Differential roles of GDF15 and FGF21 in systemic metabolic adaptation to the mitochondrial integrated stress response

HIGHLIGHTS
- Hepatic mitoribosomal defect in LKO mice leads to the ISR\textsuperscript{mt} and metabolic reprogramming
- LKO mice have increased insulin sensitivity and are resistant to diet-induced obesity
- GDF15 regulates body weight and fat mass and prevents hepatic steatosis in LKO mice
- FGF21 improves glucose clearance, energy expenditure, and thermogenesis in LKO mice

Kang et al., iScience 24, 102181 March 19, 2021 © 2021 The Authors.
https://doi.org/10.1016/j.isci.2021.102181
Differential roles of GDF15 and FGF21 in systemic metabolic adaptation to the mitochondrial integrated stress response

Seul Gi Kang,1,2 Min Jeong Choi,1,2 Saet-Byel Jung,1 Hyo Kyun Chung,1 Joon Young Chang,1,2 Jung Tae Kim,1,2 Yea Eun Kang,1,7 Ju Hee Lee,1,7 Hyun Jung Hong,1,2 Sang Mi Jun,3,4 Hyun-Joo Ro,3,4 Jae Myoung Suh,5 Hail Kim,5 Johan Auwerx,6 Hyon-Seung Yi,1,2,7,8,* and Minho Shong1,2,7,9,*

SUMMARY
Perturbation of mitochondrial proteostasis provokes cell autonomous and cell non-autonomous responses that contribute to homeostatic adaptation. Here, we demonstrate distinct metabolic effects of hepatic metabokines as cell non-autonomous factors in mice with mitochondrial OxPhos dysfunction. Liver-specific mitochondrial stress induced by a loss-of-function mutation in Crif1 (LKO) leads to aberrant oxidative phosphorylation and promotes the mitochondrial unfolded protein response. LKO mice are highly insulin sensitive and resistant to diet-induced obesity. The hepatocytes of LKO mice secrete large quantities of metabokines, including GDF15 and FGF21, which confer metabolic benefits. We evaluated the metabolic phenotypes of LKO mice with global deficiency of GDF15 or FGF21 and show that GDF15 regulates body and fat mass and prevents diet-induced hepatic steatosis, whereas FGF21 upregulates insulin sensitivity, energy expenditure, and thermogenesis in white adipose tissue. This study reveals that the mitochondrial integrated stress response (ISRmt) in liver mediates metabolic adaptation through hepatic metabokines.

INTRODUCTION
Mitochondria are frequently exposed to conditions of stress, which induce mitochondrial quality control mechanisms that are essential to maintain mitochondrial function (Sorrentino et al., 2018). Cell-autonomous communication from the mitochondria to the nucleus in response to mitochondrial stress has been well-documented in multiple species (Cagin and Enriquez, 2015; Quiros et al., 2017). Concurrently, cell non-autonomous factors are induced by mitochondrial stress, resulting in the communication between tissues that regulate selective gene expression, metabolic reprogramming, and organismal longevity (Durieux et al., 2011; Forstrom et al., 2019; Kim et al., 2013; Quiros et al., 2016). These elaborated processes have been characterized as a part of the mitochondrial integrated stress response (ISRmt), which results from primary defects in mitochondrial DNA replication, the electron transport chain, and mitoribosomal translation (Choi et al., 2020; Chung et al., 2017b; Durieux et al., 2011; Forstrom et al., 2019; Khan et al., 2017; Martinus et al., 1996; Michel et al., 2015; Quiros et al., 2017).

The liver coordinates systemic metabolism by controlling hepatic metabolic function and regulating metabolism in peripheral tissues. Hepatocyte mitochondria are essential for the maintenance of metabolic plasticity and flexibility (Koliaki and Roden, 2016), and consistent with this, recent studies have shown that mouse models of hepatic mitochondrial dysfunction have alterations in their systemic metabolism, including changes in insulin sensitivity, energy expenditure (EE), and their response to diet-induced obesity (Cho et al., 2017; Kulkarni et al., 2016; Lee et al., 2017; Pospisilik et al., 2007). These findings suggest that the hepatic adaptation to mitochondrial stress may affect systemic energy metabolism through alterations to substrate utilization in the liver and the induction of metabokines that are secreted and can modulate energy metabolism. However, the significance of these hepatic metabokines in the control of systemic metabolism has not been studied extensively.
Growth differentiation factor 15 (GDF15) and fibroblast growth factor 21 (FGF21) are representative metabokines that are responsive to mitochondrial diseases (Kalko et al., 2014; Lehtonen et al., 2016; Lovadi et al., 2017; Montero et al., 2016; Morovat et al., 2017; Yatsuga et al., 2015), and their expression is stimulated through ATF4, CHOP, and XBP1, key components of the integrated stress response (Chung et al., 2017b; Forsstrom et al., 2019; Jiang et al., 2014; Khan et al., 2017; Kim et al., 2013; Patel et al., 2019; Zhang et al., 2018).

These two metabokines have been well-documented as modulators to improve numerous metabolic processes or diseases. One of the representative roles of GDF15 is its anorexigenic effect causing a reduction of body weight, which was first described in mice overexpressing GDF15 (Johnen et al., 2007). A subsequent study showed that mice administered human GDF15 led to increased c-Fos activation in the area postrema and the nucleus of the solitary tract (Tsai et al., 2014). Recently, the GDNF family receptor α-like (GFRAL) has been discovered as a receptor for GDF15 mediating the anorexigenic action, but is localized only in the hindbrain (Emmerson et al., 2017; Hsu et al., 2017; Mullican et al., 2017; Yang et al., 2017). Despite the restriction of GFRAL expression in the hindbrain region of mice, there are numerous studies that cannot simply be explained by the anorexigenic action via GFRAL, including insulin sensitivity, lipolysis in adipose tissue, anti-inflamatory action, alleviation of hepatic steatosis, and muscle atrophy (Chrysovergis et al., 2014; Chung et al., 2017a, 2017b; Garfield et al., 2019; Jung et al., 2018; Zhang et al., 2018).

The physiological role of FGF21 also has an overlapping functional spectrum with GDF15, especially in terms of energy metabolism. FGF21 was described as a novel metabolic regulator enhancing glucose uptake in primary human adipocytes and reducing blood glucose in genetically obese mice administered FGF21 (Kharitonenkov et al., 2005). During fasting or a ketogenic diet, the expression of FGF21 is dependent on the peroxisome proliferator-activated receptor α (PPAR α), which mediates hepatic lipid oxidation, ketogenesis, and gluconeogenesis (Badman et al., 2007, 2009; Inagaki et al., 2007; Potthoff et al., 2009). Moreover, the cross talk between the liver and brain is mediated by FGF21, which regulates glucose homeostasis during prolonged fasting (Liang et al., 2014) and refeeding (Markan et al., 2014), sugar preference in response to carbohydrate intake (von Holstein-Rathlou et al., 2016), and the protein status (Hill et al., 2019). Similar to GDF15, FGF21 reduces the body weight through a non-adipose tissue effect; increases insulin sensitivity, adaptive thermogenesis, and uncoupling protein 1 (UCP1)-independent EE; and reverses hepatic steatosis (BonDurant et al., 2017; Chen et al., 2017; Desai et al., 2017; Hill et al., 2019; Ost et al., 2016; Pereira et al., 2017; Veniant et al., 2015; Xu et al., 2009). However, despite similar metabolic roles and induction mechanism, few studies distinguished between the differing roles of GDF15 and FGF21 in the context of metabolism.

Genetic or pharmacological inhibition of mitochondrial oxidative phosphorylation (OxPhos) results in the activation of cell-autonomous mitochondrial stress signaling, which involves the activation of the mitochondrial unfolded protein response (UPRmt) and mitophagy, as well as the secretion of cell non-autonomous factors (Forsstrom et al., 2019; Sorrentino et al., 2018). Mice with a tissue-specific deficiency of Crif1, which encodes a protein of the large subunit of the mitochondrial ribosome, have markedly impaired mitoribosome-mediated translation and display many molecular features of the ISRmt, including both cell-autonomous and non-autonomous responses (Choi et al., 2020; Chung et al., 2017b; Kim et al., 2012). In the present study, we have explored the effects of hepatic mitochondrial OxPhos dysfunction on energy metabolism in the liver and other key metabolic tissues. We have characterized the adaptive response to mitochondrial OxPhos dysfunction in the liver and investigated its effects on insulin sensitivity and EE. Using double knockout mice (LKO/Gdf15+/−, LGKO and LKO/Fgf21+/−, LFKO), we have identified distinct roles of hepatic GDF15 and FGF21 in response to ISRmt. GDF15 regulates body fat mass and protects against hepatic steatosis, whereas FGF21 increases insulin sensitivity and uncoupling protein (UCP1)-mediated thermogenesis in inguinal adipose tissue (iWAT) in the context of hepatic mitochondrial dysfunction.

RESULTS
Aberrant OxPhos by Crif1 deletion is associated with ISRmt and impairments in insulin signaling and insulin-stimulated glucose uptake in hepatocytes
To determine the impact of hepatic mitochondrial OxPhos dysfunction on systemic energy metabolism, we generated liver-specific Crif1 knockout (LKO) mice through selective disruption of Crif1 in hepatocytes using the Cre-loxP system (Figures S1A and S1B). The generated mice did not show any obvious
Figure 1. The livers of liver-specific Crif1-deficient mice exhibit altered glucose metabolism and impaired insulin signaling

(A) Gross morphology of Ctrl and LKO mice at 8 weeks of age.

(B) Western blot analysis showing lower levels of CRIF1 and subunits of the OxPhos complex in the livers of Ctrl and LKO mice. The results of one representative experiment of the two conducted are shown.

(C) BN-PAGE analysis of the assembled OxPhos complex in the livers of Ctrl and LKO mice (*: abnormal sub-complexes).

(D) Representative transmission electron microscopic images of livers from Ctrl and LKO mice (n = 4). The white arrows indicate hepatic glycogen granules.

(E and F) Quantitative PCR analysis of UPRmt mediators (E) and UPRer and transcription factors involved in the mitochondrial stress response (F) in the livers of Ctrl and LKO mice (n = 4–5 biological replicates from three independent experiments).

(G) Western blot analysis of UPRmt and UPRer mediators in the livers of Ctrl and LKO mice. The results of one representative experiment out of the three conducted are shown. Data are mean ± SEM and were analyzed using Student’s t test (*p < 0.05 versus Ctrl).

(H) OCR (left panel) and individual parameters (right panel) in primary hepatocytes isolated from Ctrl and LKO mice (n = 10 biological replicates from two independent experiments) treated with oligomycin (2 μg/mL), CCCP (10 μM), or rotenone (1 μM). Basal respiration, ATP production, and proton leakage were measured. **(I) Glucose Oligo 2-DG (left panel) and ECAR (right panel) in primary hepatocytes treated with glucose (25 mM) or oligomycin (2 μg/mL). The results are shown as mean ± SEM and were analyzed using Student’s t test (*p < 0.05 versus Ctrl).
Defective hepatic OxPhos is associated with higher systemic insulin sensitivity and energy expenditure

Chow-fed LKO mice exhibited similar body masses to control mice at 30 weeks of age (Figure 2A). Although LKO hepatocytes were characterized by large nuclei and cytoplasmic volumes, the liver mass was similar to that of control mice, whereas the fat mass of LKO mice was significantly lower than that of controls (Figures 2B and S2A). To determine whether poor hepatic OxPhos function affects systemic insulin sensitivity, we conducted glucose or insulin tolerance testing in mice fed a chow diet at 8 weeks of age. Interestingly, the glucose and insulin tolerance of LKO mice was superior to that of control mice (Figures 2C and 2D). In addition, the hepatic Kupffer cells of LKO mice were characterized by the abundant presence of mononuclear cells in the centrilobular areas (Figure S1C). Although liver mass and blood glucose levels of LKO mice were similar to those of controls, the glucose uptake by primary hepatocytes from LKO mice was much higher than that by control cells, but the effect of insulin on glucose uptake into hepatocytes (Figures 1H–IJ). The basal glucose uptake by primary hepatocytes from Ctrl and LKO mice was calculated after oligomycin treatment, and the maximal and non-mitochondrial respiration were calculated after CCCP and rotenone treatment, respectively.

Next, we conducted 2-deoxy-D-glucose (2DG) uptake analysis to determine whether the higher rate of glucose uptake into hepatocytes (Figures 1H–IJ). The basal glucose uptake into hepatocytes was also higher in LKO mice than in controls, but the effect of insulin on glucose uptake into hepatocytes was attenuated in LKO hepatocytes (Figure 1K). Subsequently, we measured insulin-stimulated AKT phosphorylation in cultured hepatocytes and found significantly lower insulin-induced phosphorylation of AKT at Ser473 and Thr308 in primary LKO hepatocytes than in control hepatocytes (Figure 1L). Taken together, these findings imply that hepatic OxPhos dysfunction in LKO mice is associated with activation of ISRmt and lower insulin-stimulated AKT activation, but greater glycolysis and glucose uptake.

Figure 1. Continued

were calculated after oligomycin treatment, and the maximal and non-mitochondrial respiration were calculated after CCCP and rotenone treatment, respectively.

(I) Glycolysis assay (left panel) and glycolytic parameters (right panel) in primary hepatocytes isolated from the livers of Ctrl and LKO mice (n = 6 biological replicates from two independent experiments). Non-glycolytic acidification was calculated after the addition of 2-DG (50 mM). Glycolysis, glycolytic capacity, and glycolytic reserve were calculated after the addition of glucose (10 mM) and oligomycin (1 μM), respectively.

(J) Quantitative PCR analysis of Glut1 and Glut2 mRNA expression in livers from 8-week-old Ctrl and LKO mice (n = 6 biological replicates from two independent experiments). Insulin (1 μM) was added 20 min before the measurements.

(K) Glucose uptake by primary hepatocytes from Ctrl and LKO mice (n = 6 biological replicates from two independent experiments). Insulin (1 μM) was added 20 min before the measurements.

(L) Western blot analysis of insulin signaling after the addition of insulin (200 nM) for 15 min to primary hepatocytes isolated from Ctrl and LKO mice. The results of one representative experiment of the two conducted are shown. Data are mean ± SEM and were analyzed using two-way ANOVA followed by Scheff's post-hoc test in (K) and Student's t test in (E and F) and (H–J) (*p < 0.05 versus Ctrl or Ctrl-Vehicle). See also Figure S1.
Figure 2. Liver-specific Crif1-deficient mice exhibit superior energy metabolism and are protected against diet-induced obesity

Mice fed a chow diet were used in (A–K) and mice fed an HFD for 8 weeks were used in (L–S).

(A) Body masses of Ctrl and LKO mice from 6 to 31 weeks of age (n = 10 biological replicates from two independent experiments).

(B) Body composition of Ctrl and LKO mice (n = 5–6 biological replicates from two independent experiments).

(C) Glucose tolerance test (GTT) (left panel) and glucose area under the curve (AUC) (right panel) for Ctrl and LKO mice (n = 7 biological replicates from three independent experiments).

(D) Insulin tolerance test (ITT) (left panel) and glucose area under the curve (AUC) (right panel) for Ctrl and LKO mice (n = 7 biological replicates from three independent experiments).

(E) Blood glucose concentrations of Ctrl and LKO mice fasted for 6 h (n = 10 biological replicates from five independent experiments).

(F) Serum insulin concentrations in Ctrl and LKO mice fasted for 6 h (n = 10–12 biological replicates from three independent experiments).

(G) Measurement of energy expenditure (EE) per metabolic body mass of Ctrl and LKO mice (n = 7–8 biological replicates).

(H and I) Correlation analysis between EE and total body mass (TBM) (H) and ANCOVA-adjusted EE (I) in Ctrl and LKO mice.

(J and K) Daily food intake (J) and cumulative food intake over 7 days (K) in mice (n = 7–9 biological replicates from five experiments).

(L) Body mass (n = 5 biological replicates from three independent experiments).

(M) Body composition in Ctrl and LKO mice (n = 7 biological replicates from two independent experiments).

(N) Representative images of H&E-stained liver sections, showing a central vein, from Ctrl and LKO mice (n = 5–6 biological replicates).

(O) Quantitative PCR analysis of the expression of genes involved in lipid metabolism in the livers of Ctrl and LKO mice (n = 4–5 biological replicates from two independent experiments).

(P) Glucose tolerance test (GTT, left panel) and glucose area under the curve (AUC, right panel) for Ctrl and LKO mice (n = 5 biological replicates from three independent experiments).
2D), which translated into lower blood glucose and serum insulin concentrations (Figures 2E and 2F). Alongside the lower basal blood glucose levels in LKO mice, the fasting-induced expression of glucose 6-phosphatase (G6pase) and phosphoenolpyruvate carboxykinase (Pepck), which are the rate-limiting enzymes in gluconeogenesis, was also lower in LKO mice than in controls (Figure S2B). Furthermore, the homeostatic model assessment for insulin resistance (HOMA-IR) suggested that LKO mice had significantly higher systemic insulin sensitivity than controls (Figure S2C), despite the disruption to hepatic insulin signaling. The serum triglyceride concentration of LKO mice was similar to that of controls, but the total cholesterol concentration was lower (Figures S2D and S2E).

To explore the effects of hepatic OxPhos dysfunction on systemic EE, we measured O2 consumption and CO2 production by indirect calorimetry. LKO mice had a higher EE/metabolic body mass (body mass0.75) ratio than control mice (Figure 2G). Plots of individual data and the ANCOVA-adjusted EE with body mass as a covariate revealed that LKO mice had significantly higher EE than controls, even after the effects of mass were eliminated (Figures 2H and 2I). The factors that influence total EE in the mice were then assessed by analyzing locomotor activity (Figure S2F), body temperature (Figure S2G), and food intake (Figures 2J and 2K), which were all similar in LKO and control mice. LKO mice had a tendency toward a lower respiratory quotient (RQ) than control mice (Figure S2H), but there was no difference in the serum concentration of the ketone body β-hydroxybutyrate (BHB) (Figure S2I). Taken together, these data suggest that hepatic OxPhos dysfunction is associated with higher systemic insulin sensitivity and EE, but not differences in body temperature or food intake, even though insulin signaling and gluconeogenesis are impaired in the livers of LKO mice.

**LKO mice are protected against diet-induced obesity and insulin resistance**

To determine whether hepatic OxPhos dysfunction alleviates metabolic stress, LKO mice and controls were fed a high-fat diet (HFD) for 8 weeks from 6 weeks of age. LKO mice were already gaining significantly less body mass than controls after 1 week of HFD feeding (Figure 2L). After 8 weeks, the masses of iWAT, epididymal white adipose tissue (eWAT), and brown adipose tissue (BAT) in LKO mice were lower than those of controls (Figure S2J). Thus, the lower body mass of LKO mice fed an HFD was likely the result of resistance to fat accumulation (Figure 2M). LKO mice also showed lower hepatic lipid accumulation (Figure 2N), which was associated with lower hepatic expression of Srebp1, Srebp1c, and Cd36 (Figure 2O). The glucose and insulin tolerance of LKO mice fed an HFD were higher than those of control mice on the same diet (Figures 2P and 2Q), which was consistent with the lower blood glucose, insulin, and HOMA-IR in the fasted LKO mice (Figures S2K, S2L, and S2M). The serum concentrations of triglyceride were similar in LKO mice and controls (Figure S2N), but the total cholesterol concentration was lower in HFD-fed LKO mice (Figure S2O).

Next, we assessed the EE of the mice by indirect calorimetry. When consuming an HFD, the EE adjusted for metabolic body mass was significantly higher in LKO than in control mice during both the night and daytime (Figure 2R), but the ANCOVA-adjusted EE was similar in the two genotypes (Figure 2S). RQ tended to be lower in LKO mice (Figure S2P), but the serum BHB concentrations were similar in the two groups (Figure S2Q). Taken together, these results demonstrate that LKO mice are resistant to diet-induced obesity and protected against hepatic steatosis and insulin resistance when fed an HFD.

**The adipose tissue of LKO mice exhibits enhanced insulin signaling and fatty acid oxidation**

To assess the insulin sensitivity of key metabolic tissues in LKO mice, we evaluated insulin signaling and action in the liver, iWAT, eWAT, BAT, and gastrocnemius muscle (GM) after the intraperitoneal injection of insulin (4 U/kg). AKT phosphorylation at Ser473 and Thr308 was significantly lower in the livers of LKO mice than controls (Figure 3A), but insulin-stimulated AKT phosphorylation at Ser473 and Thr308 was much higher in both the iWAT and eWAT of LKO mice (Figures 3B and 3C). However, the AKT
phosphorylation in GM was similar in LKO and control mice, but the AKT phosphorylation at Ser 473 in BAT was decreased in LKO mice (Figures S3A and S3B).

LKO mice exhibited cellular heterogeneity in their iWAT, but not BAT, upon histological analysis (Figure 3D). Moreover, the expression of \textit{Glut4}, \textit{Ppar\alpha}, \textit{Cpt1\alpha}, and acyl-CoA dehydrogenase medium chain (\textit{Acadm}) and very long chain (\textit{Acadvl}) were significantly increased in the iWAT (Figure 3E), but not in the eWAT, BAT, or GM of LKO mice (Figures S3C and S3D). Interestingly, UCP1 expression was elevated in the iWAT and eWAT of LKO mice. Furthermore, the phosphorylation of CREB at Ser133 was significantly increased in the LKO iWAT and eWAT, but not in the BAT or GM (Figure 3F).

**Figure 3.** The white adipose tissue of liver-specific \textit{Crif1}-deficient mice exhibits greater insulin signaling and fatty acid metabolism

(A–C) Western blot analysis of AKT phosphorylation in the liver (A), iWAT (B), and eWAT (C) of Ctrl and LKO mice (n = 3 biological replicates per group). Mice were fasted for 6 h and then administered intraperitoneally with insulin (4 U/kg). One representative experiment of the two conducted is shown.

(D) Representative images of hematoxylin and eosin-stained iWAT and BAT sections from Ctrl and LKO mice (n = 4 biological replicates).

(E) Quantitative PCR analysis of the expression of genes involved in glucose uptake and fatty acid metabolism in the iWAT of Ctrl and LKO mice (n = 6 biological replicates from two independent experiments).

(F) Western blot analysis of signaling upstream of UCP1 in the iWAT of Ctrl and LKO mice (n = 3 biological replicates). The results of one representative experiment of the three conducted are shown. Mice were fed a chow diet. Data are mean ± SEM and were analyzed using two-way ANOVA followed by Scheff’s post-hoc test in (A–C) and Student’s t test in (E) and (F) (*p < 0.05 versus Ctrl or Ctrl-Saline). See also Figure S3.
increased in the iWAT of LKO mice (Figure 3F). This is consistent with the induction of adipose UCP1 expression in LKO mice. Taken together, these data suggest that hepatic OxPhos dysfunction is associated with enhanced insulin signaling and fatty acid oxidation in adipose tissue depots.

Transcriptome analysis identifies altered biological pathways and transcripts associated with adaptive mitochondrial stress in LKO mice

To better understand the effects of hepatic OxPhos dysfunction on systemic energy metabolism, multi-tissue transcriptomic analysis was performed on the liver, iWAT, GM, and hypothalamus of the mice. A Venn diagram shows the number of transcripts with a significant > ±1.5-fold difference in the liver (1,325), iWAT (251), GM (36), and hypothalamus (17) of LKO mice (Figures S4A and S4B, and Table S2). Pyruvate dehydrogenase kinase 4 (Pdk4), switching the glucose catabolism to fatty acid utilization, and alkaline ceramidase 2 (Acer2), responding to DNA damage, were commonly increased in liver, iWAT, and GM of LKO mice. The livers of LKO mice exhibited higher expression of transcripts related to the ISRmt, including that of transcripts encoding transcription factors (Nupr1, Atf3, and Atf5), hepatic metabokines (Gdf15 and Fgf21), and proteins involved in single-carbon (1C) metabolism (Mthfd1f and Mthfd2) (Figure 4A). Gene set enrichment analysis (GSEA) suggested that Crif1 deficiency activated glycolysis (Figure 4B, left panel). Functional annotation charts based on the KEGG pathway also indicated that gene sets of glutamine, 1C, glycogen, and fatty acid metabolism were increased in the liver of LKO mice (Figures S4C and S4D, and Table S3), whereas steroid hormone biosynthesis and transcription factors involved in lipid metabolism were downregulated in LKO livers (Figures 4B, right panel, and 4E).

The transcripts associated with browning (Ucp1, Dio2, Cidea, and Cox7a1) and fatty acid oxidation (Ppara, Cpt1b, and Cd36) were upregulated in the iWAT of LKO mice (Figure 4C). The functional annotation chart and GSEA in iWAT revealed that gene sets related to PPAR, PI3K-AKT, and the cyclic adenosine 3’,5’-monophosphate (cAMP) signaling pathways were significantly enriched in the LKO mice (Figures 4D and 4E, and Table S3), which was confirmed by an increase in insulin signaling in the WAT of LKO mice (Figures 3B and 3F).

Cell non-autonomous factors induced during the ISRmt play a key role in inter-organ communication and the reprogramming of systemic energy metabolism. We therefore analyzed the differentially expressed genes (DEGs) termed as secreted proteins in liver and found that transcripts classified as growth factor, immune response, lipoprotein, and mediators related with lipid and glucose metabolism were associated with defective OxPhos in liver (Figure 4F). Among the transcripts that have known to improve the insulin sensitivity, Fgf21 (15.5-fold change) and Gdf15 (7.2-fold change) were mostly increased in the liver of LKO mice with significance. Mitochondrial OxPhos dysfunction increased not only hepatic Gdf15 and Fgf21 mRNA expression but also the serum concentrations of GDF15 and FGF21 in the LKO mice (Figures 4G and 4H). In addition, the expression of β-klotho, a co-receptor for FGF21, was also high in the iWAT of LKO mice, which might be because of greater effects of FGF21 (Figure 4I). Taken together, these data show that mitochondrial OxPhos dysfunction in the liver alters the hepatic transcriptome involved in coordinating the ISRmt (including cell-autonomous and non-cell autonomous factors), and these hepatic changes were associated with greater insulin action in adipose tissues and the regulation of systemic energy homeostasis.

Distinct roles of the hepatic metabokines GDF15 and FGF21 in systemic energy metabolism

Although the physiological role of GDF15 and FGF21 have been well established through respective studies using pharmacological and genetic approaches, it is still unclear how concurrently induced metabokines differently act and which is more potential to improve the metabolism.

Therefore, to investigate the roles of these major hepatic metabokines in LKO mice, we generated LKO mice with global Gdf15 deletion (LGKO) or global Fgf21 deletion (LFKO) on a C57BL/6 background (Figures S5A and S5B). LGKO and LFKO mice exhibited much lower expression of Gdf15 and Fgf21, respectively, than control mice (Figures S5C and S5D). Interestingly, deficiency of one of these metabokines did not affect the expression of the other metabokine in LKO mice (Figures S5E and S5F).

Next, we compared the effects of the two hepatic metabokines on systemic energy homeostasis. LGKO mice had higher body and fat mass than LKO mice (Figures 5A and 5B). Although the ablation of GDF15 increased the food intake of both the GKO and LGKO mice, LKO mice (with endogenous plasma
concentrations of GDF15 of 308G88.04 pg/mL) consumed similar amounts of food as controls (Figure 5C).

By contrast, LFKO mice exhibited similar body and fat mass gains to LKO mice (Figures 5D and 5E) as well as food intake (Figure 5F). glucose tolerance test (GTT) revealed that glucose clearance was better in LKO and LGKO mice than in controls (Figure 5G), but LGKO mice showed an intermediate glucose disposal rate during insulin tolerance test (ITT) (Figure 5H), which suggests that GDF15 affects insulin-stimulated glucose disposal. By contrast, LFKO mice showed high blood glucose concentrations 15 min after glucose

Figure 4. Liver-specific Crif1 deficiency increases the production of metabokines in liver

(A) Volcano plot showing the DEGs in the liver of LKO mice. The colored dots indicate the DEGs with \( \geq 1.5 \)-fold difference from Ctrl mice. The red and blue dots indicate the upregulated and downregulated transcripts, respectively.

(B) Gene set enrichment analysis (GSEA) using DEGs in the liver of Ctrl and LKO mice.

(C and D) Volcano plot showing the DEGs (C) and top-ranked functional annotation chart (D) in the iWAT of LKO mice. Functional annotation was categorized using the KEGG pathway in DAVID (ver. 6.8), and the results are ordered according to gene number.

(E) GSEA showing the upregulated gene set in the iWAT of LKO mice.

(F) Heatmap of the DEGs classified as “Secreted proteins” in the cellular compartment category (\( \geq 2 \)-fold difference, \( p < 0.05 \) versus Ctrl mice). The genes in red were the two top-ranked transcripts, Fgf21 and Gdf15 in the liver of LKO mice.

(G) Quantitative PCR analysis of Gdf15 and Fgf21 mRNA expression in Ctrl and LKO livers (n = 5–6 biological replicates from four independent experiments).

(H) Serum GDF15 (n = 6–7 biological replicates) and FGF21 (n = 4–5 biological replicates) in Ctrl and LKO mice. Three experiments were performed.

(I) Quantitative PCR analysis of Klb and Fgfr1c mRNA expression in adipose tissue of mice (n = 6 biological replicates).

The mice were studied at 8–9 weeks of age and fed a chow diet. Data in (G–I) are mean ± SEM. Statistical analyses were performed using Student’s t test in (G–I) (*\( p < 0.05 \), **\( p < 0.01 \), ***\( p < 0.001 \) versus Ctrl). The data in (D) were analyzed using a modified Fisher’s exact p value (*\( p < 0.05 \), **\( p < 0.01 \), ***\( p < 0.001 \)).

Un.d, undetectable. See also Figure S4.

concentrations of GDF15 of 308G88.04 pg/mL) consumed similar amounts of food as controls (Figure 5C).

By contrast, LFKO mice exhibited similar body and fat mass gains to LKO mice (Figures 5D and 5E) as well as food intake (Figure 5F). glucose tolerance test (GTT) revealed that glucose clearance was better in LKO and LGKO mice than in controls (Figure 5G), but LGKO mice showed an intermediate glucose disposal rate during insulin tolerance test (ITT) (Figure 5H), which suggests that GDF15 affects insulin-stimulated glucose disposal. By contrast, LFKO mice showed high blood glucose concentrations 15 min after glucose
Figure 5. GDF15 regulates body and fat mass, and FGF21 regulates glucose clearance in liver-specific Crif1-deficient mice fed a chow diet

(A) Body masses of Ctrl, LKO, GKO, and LGKO mice (n = 7 biological replicates from five independent experiments).
(B) Body composition, measured by DXA, of Ctrl, LKO, GKO, and LGKO mice (n = 7–11 biological replicates from three independent experiments).
(C) Cumulative food intake over 5 days in Ctrl, LKO, GKO, and LGKO mice housed in individual cages (n = 7–11 biological replicates).
(D) Body masses of Ctrl, LKO, FKO, and LFKO mice (n = 8–12 biological replicates from two independent experiments).
(E) Body composition, measured by DXA, of Ctrl, LKO, FKO, and LFKO mice (n = 7–10 biological replicates from two independent experiments).
(F) Cumulative food intake over 5 days in Ctrl, LKO, FKO, and LFKO mice (n = 8–12 biological replicates from two independent experiments).
(G) Glucose tolerance test (left panel) and glucose area under the curve (AUC, right panel) after fasting for 6 h in Ctrl, LKO, GKO, and LGKO mice (n = 6–7 biological replicates per group from three independent experiments).
(H) Insulin tolerance test (left panel) and glucose area under the curve (AUC, right panel) in Ctrl, LKO, GKO, and LGKO mice fasted for 6 h (n = 6–7 biological replicates per group from three independent experiments).
challenge and intermediate insulin tolerance, when compared with LKO mice, which indicates that FGF21 affects acute glucose clearance and disposal (Figures 5I and 5J). Taken together, these data suggest that hepatic GDF15 secretion in the context of the ISR™ regulates body and fat mass, regardless of food intake, whereas hepatic FGF21 has a glucose-lowering effect. Thus, both metabokines influence insulin-stimulated glucose disposal.

Fgf21 deficiency is associated with less browning and lower systemic energy expenditure in LKO mice

Next, to dissect the mechanism whereby hepatic metabokines affect insulin signaling in the WAT and the EE of LKO mice, we measured the insulin-induced AKT phosphorylation in the iWAT of double knockout mice. LGKO mice showed consistently an increase in insulin-induced AKT phosphorylation at Thr308 in iWAT (Figures 6A and 5A). Moreover, the high expression of Glut4, Ucp1, and Cpt1a/b that was identified in the iWAT of LKO mice remained in LGKO mice (Figure 6B), whereas LFKO mice showed a decrease in both phosphorylation at Thr308 and Ser473 in iWAT following intraperitoneal insulin injection (Figures 6B, 6C, and 5B). Interestingly, the expression of Ucp1 and Cpt1a/b was significantly lower in LFKO mice than in LKO mice (Figure 6D). EE was significantly higher in LGKO mice than in control mice during the night (Figure 6E), even though the physical activity of the two groups was similar (Figure 6F). By contrast, the high EE in LKO mice (day, p = 0.1385; night, p = 0.0535) was significantly reduced in LFKO mice, despite similar physical activity (Figures 6G and 6H), which suggests that FGF21 is required for the high EE in LKO mice. Taken together, these data suggest that FGF21 increases not only insulin signaling and EE but also the expression of genes involved in energy metabolism in the iWAT. However, GDF15 is involved the glucose disposal mediated by insulin, not required for the improvements in energy homeostasis in mice that have aberrant hepatic OxPhos.

GDF15 contributes to the prevention of hepatic steatosis in LKO mice fed a high-fat diet

To verify whether hepatic metabokines confer resistance to diet-induced obesity, all the groups of mice were fed an HFD for 8 weeks. LGKO mice showed greater body mass gain than LKO mice, but that of the LFKO mice was similar to that of the LKO mice when consuming an HFD (Figures 7A and 7B). The masses of the iWAT, eWAT, and BAT depots were much higher in LGKO mice than in LKO mice, but Fgf21 deficiency did not alter the masses of adipose tissue depots in LKO mice (Figures 7C and 7D), which suggests that GDF15 influences the body and fat mass of LKO mice fed an HFD.

The glucose clearance during GTT by HFD-fed LGKO and LFKO mice was similar to that of LKO mice (Figures 7E and 7G), but LGKO mice exhibited an intermediate rate of glucose disposal after insulin stimulation (Figures 7F and 7H), which implies that GDF15, but not FGF21, is required for effective insulin action in mice fed an HFD. Because of the lower hepatic lipid accumulation in LKO mice fed an HFD, we next analyzed the liver histology of double knockout mice. LGKO livers contained larger numbers of intracellular lipid droplets than LKO mice, whereas LFKO livers contained fewer lipid droplets (Figure 7I). This suggests that the GDF15 that is secreted in response to the ISR™ may protect against hepatic fat deposition in LKO mice fed an HFD.

DISCUSSION

Recent studies have revealed that mitochondrial OxPhos dysfunction or proteotoxic stress can elicit an adaptive hormetic response to overcome the initiating abnormalities, which are paradoxically associated with improvements in systemic energy metabolism (Bhaskaran et al., 2018; Kleinridders et al., 2013; Pospisilik et al., 2007) and greater longevity in multiple organisms (Feng et al., 2001; Houtkooper et al., 2013; Kirchman et al., 1999; Liu et al., 2005; Owusu-Ansah et al., 2013). These benefits are thought to be mediated by metabokines (Chung et al., 2017b; Durieux et al., 2011; Kim et al., 2013; Ost et al., 2016). The liver
is one of the first organs to respond to dietary factors (Kraegen et al., 1991) and demonstrates metabolic plasticity and flexibility of its mitochondria to permit adaptation to changes in bioenergetic demand (Koliaki and Roden, 2016). Liver-specific Cpt2-deficient mice exhibited improvements in metabolism that were associated with high serum concentrations of GDF15 and FGF21 (Lee et al., 2017), but the direct effects of changes in the secretion of these hepatic metabokines on energy metabolism were not described. Moreover, almost all studies have displayed the concurrent induction of GDF15 and FGF21 in response to key regulators of ISRmt, including CHOP and ATF4, but did not distinguish the metabolic role of each metabokine. In the present study, we created a mouse model of liver-specific OxPhos dysfunction and characterized the hepatic adaptive response, which we found to involve both cell-autonomous and cell non-autonomous signaling. We suggest that mitochondrial stress in hepatocytes results in (1)
Figure 7. Genetic ablation of Gdf15 in LKO mice worsens hepatic steatosis, independent of insulin sensitivity

(A) Body masses of Ctrl, LKO, GKO, and LGKO mice fed a high-fat diet (60% fat) from 6 to 14 weeks of age (n = 7 biological replicates from two independent experiments).

(B) Body masses of Ctrl, LKO, FKO, and LFKO mice fed a high-fat diet from 6 to 14 weeks of age (n = 6–8 biological replicates from two independent experiments).

(C) Tissue masses per unit body mass of Ctrl, LKO, GKO, and LGKO mice fed a high-fat diet (n = 7–8 biological replicates from two independent experiments).

(D) Tissue masses per unit body mass of Ctrl, LKO, FKO, and LFKO mice fed a high-fat diet (n = 5 biological replicates from two independent experiments).
In LKO mice, the reduction in hepatic OxPhos activates glycolysis and insulin-independent glucose uptake, which seems to compensate for the energy deprivation. Although the hepatocytes of LKO mice use different pathways for their energy production, the size of glycogen storage granules and the expression of genes involved in gluconeogenesis and lipogenesis were lower in LKO livers. Although the detailed mechanism underlying the reduction in gluconeogenesis associated with OxPhos dysfunction was not defined in the present study, we identified reductions in the expression of transcription factors that regulate glucose and lipid metabolism, including Foxo3, ChREBP, and Srebp1/2, in the livers of LKO mice, which suggests that there is cross talk between mitochondrial OxPhos and the nucleus to maintain gluconeogenesis and lipid metabolism. Another effect of mitochondrial OxPhos deficiency was that hepatic insulin signaling, as assessed by the measurement of insulin-induced AKT phosphorylation, was markedly impaired in LKO livers. In contrast to the phenotype of the LKO mice, liver-specific apoptosis-inducing factor (Aif) knockout mice exhibited an improvement in hepatic insulin signaling, even though hepatic OxPhos was also impaired (Pospisilik et al., 2007). This discrepancy may be due to the differing levels of proteotoxic or oxidative stress. A deficiency of hepatic Aif does not change the intracellular or extracellular reactive oxygen species (ROS) concentrations compared with controls, but Cnrf1-deficient cells exhibit significantly higher mitochondrial ROS production (Kim et al., 2012) and proteotoxic stress, which lead to additional impairments in mitochondrial OxPhos.

In the present study, we have demonstrated that GDF15 and FGF21 are hepatic metabokines that modulate systemic energy metabolism in LKO mice (Figure 7J). Metabokines are well-known biomarkers of mitochondrial pathology (Davis et al., 2016), as well as important regulators of systemic energy metabolism. The promoters of Gdf15 and Fgf21 contain binding sites for transcription factors, such as CHOP and ATF4, respectively (Chung et al., 2017b; De Sousa-Coelho et al., 2012), which increase the levels of both metabokines during the ISR. Most studies conducted to date focused on the role of single metabokines in the regulation of insulin sensitivity and EE, whereas we have distinguished the differential effects of hepatic metabokines using double knockout LKO/Gdf15−/− (LGKO) and LKO/Fgf21−/− (LFKO) mice. We have identified a role for GDF15 in the regulation of body mass, fat mass, and insulin-dependent glucose disposal in LKO mice, whereas FGF21 improves insulin sensitivity and glucose homeostasis. Moreover, FGF21 ablation reduced EE and the induction of UCP1 in the iWAT of chow diet-fed LKO mice. Interestingly, we also found that GDF15 protects against hepatic steatosis and insulin resistance in mice fed an HFD, which was in contrast to our finding of fewer hepatic lipid droplets in FGF21-deficient mice. Although the underlying mechanism whereby GDF15 protects against hepatic steatosis is unclear, our data suggest that GDF15 and FGF21 have differing roles in liver fat homeostasis.

Recent studies have demonstrated effects of FGF21 (Ost et al., 2016) and GDF15 (Ost et al., 2020) secreted by muscle using skeletal muscle-specific Ucp1 transgenic (TG) mice. The TG mice exhibited a skeletal muscle-specific mitochondrial stress response, but an improvement in systemic energy metabolism. However, contrary to our findings, these studies demonstrated that skeletal muscle-derived FGF21 was not required for the improvements in EE and insulin sensitivity (Ost et al., 2016). This discrepancy may be explained by differences in the responsiveness of mice of different ages to FGF21. The previous study was conducted in 40-week-old mice, and the serum FGF21 concentrations of the wild-type mice were ~2 ng/mL, which was 10 times higher than the concentrations in the control mice in the present study, which suggests that older mice may be FGF21 resistant. Although the molecular mechanism underlying FGF21 resistance requires elucidation (Markan et al., 2017), aging is known to increase the FGF21 concentration and is negatively
associated with FGF21 responsiveness (Villarroya et al., 2018). Another difference between the present study and that of the Ucp1-TG mice regards whether GDF15 plays an important role in the UCP1-dependent browning of iWAT. Browning in the Ucp1-TG mice was abolished in TG/Gdf15−/− mice, which contrasts with our finding that genetic ablation of Gdf15 does not alter Ucp1 induction in LKO mice. GDF15 has an anti-inflammatory role in adipose-resident macrophages because it promotes M2-like polarization (Jung et al., 2018), which is favorable for browning (Nguyen et al., 2011). Given that adipose inflammation gradually increases with age (Schaum et al., 2019), the potential for browning would be maximized in older mice through the activation of M2 macrophages. Our in vivo experiments were conducted in young mice (8–10 weeks of age), which may have reduced the impact of GDF15 on the immune cells that favor the browning of adipose tissue.

In our previous studies, we developed mice with mitochondrial OxPhos dysfunction caused by Crif1 deficiency in a tissue-specific manner (brain, adipose tissue, skeletal muscle, β-cell, and macrophage) (Choi et al., 2020; Chung et al., 2017b; Jung et al., 2018; Kim et al., 2012, 2015). However, induction of metabokines (GDF15, FGF21) were not observed in every genetic model. Mice with Crif1 deficiency in β-cells and macrophages exhibited normal or reduced expression of metabokines, respectively, whereas deletion of Crif1 in adipose and skeletal muscle showed significantly increased metabokine levels, suggesting that the mitohormetic effects and induction mechanism can vary tissue specifically.

As mentioned, we developed adipose-specific Crif1 KO mice (AdKO) (Choi et al., 2020) and observed the roles of GDF15 and FGF21 in this model. We postulated that the metabolic effects of these metabokines can vary depending on which tissue produces the metabokines. Several studies suggest that liver, but not the adipose tissue, produces the circulating FGF21 in DIO mice (Markan et al., 2014) or in mice exposed to cold (Ameaka et al., 2019), which regulated glucose disposal or core body temperature, respectively. At least in these conditions (DIO, acute cold exposure), FGF21 derived from adipose tissue was insufficient to enhance the glucose disposal or regulate core body temperature. In agreement with these studies, AdKO mice fed a chow diet showed only modest changes in glucose and insulin tolerance as well as EE despite induction of GDF15 and FGF21 in white adipose tissue. In contrast to ADKO mice, LKO mice fed a chow diet showed improved insulin tolerance. The effects on hepatic steatosis in mice fed an HFD also differed between the two studies. In DIO-AdKO mice, both GDF15 and FGF21 protected from hepatic fat accumulation, whereas in DIO-LKO mice, only GDF15 showed a protective effect on hepatic fat accumulation.

The previous study using male GDF15KO mice exhibited similar EE and cumulated food intake as controls, but the fat mass was significantly increased in GDF15KO mice at 12–14 weeks of age (Tsai et al., 2013). However, the male GKO mice used in this study manifested similar body and fat mass with controls at 10 weeks of age, which was consistent with another study observing the body and fat mass in GDF15KO mice up to 95 weeks of age (Ost et al., 2020). Moreover, unlike with the previous study, our male GKO and LGKO mice exhibited significantly increased cumulative food intake for 5 days. This discrepancy can be caused by differences in the normalization of food intake. The previous study displayed modest changes in food intake, which was normalized to the total body weight, despite a different body composition (Tsai et al., 2013). However, according to the guidelines for measuring energy intake and expenditure in mice, simple division by body weight can overlook the relationship between body composition (fat and lean mass) and energy metabolism (Tschop et al., 2011). This approach can only be adjusted in the case that the intercept of regression line between mass and EE is zero.

GDF15 has a potent anorexigenic effect that is exerted via activation of the brainstem receptor GFRAL (Hsu et al., 2017; Yang et al., 2017). Recent work has suggested that GDF15 administration affects food intake by activating GFRAL (Borner et al., 2020). Although the mice were administered a low dose of GDF15 (20 μg/mL) in this study, the dose is still high compared with the normal physiological levels of GDF15 (~100 pg/mL in C57BL/6 mice) (Patel et al., 2019). However, LKO mice with serum GDF15 concentrations of ~300 pg/mL did not exhibit any differences in food intake, which was consistent with the phenotypes of several mouse models that had endogenous serum GDF15 concentrations of ~400 pg/mL (Choi et al., 2020; Kim et al., 2018; Ost et al., 2020). Pharmacological doses of recombinant GDF15 induce emesis and nausea, and lead to about 60-fold higher concentrations than the serum GDF15 concentrations in the LKO mice. Further evidence may be obtained from study of the soluble form of GFRAL, GFRAL-B (Li et al., 2005). GFRAL has two splice variants: GFRAL-A, a membrane-bound full-length form, and GFRAL-B, which lacks
the cysteine-rich domain 3. Although the expression of GFRAL-A and B is restricted to certain brain regions, it still needs to be determined whether the soluble form of GFRAL can bind to circulating GDF15. GDF15 activity and the concentration threshold required for its effects on systemic energy metabolism may be regulated by this soluble form of GFRAL. Therefore, further study is required to determine whether soluble GFRAL has a role in metabolism.

Limitations of the study
Although the expression of Fgf21 and Gdf15 was only increased in the livers of LKO mice, it is difficult to exclude an effect of the basal expression of these genes in other tissues on the mouse phenotype. According to previous study findings, global Gdf15 knockout mice does not alter blood glucose, insulin tolerance, or EE in male mice (Tsai et al., 2013). In addition, Fgf21 knockout mice did not show a difference in blood glucose in the fed state (Liang et al., 2014; Potthoff et al., 2009). However, during fasting conditions, Fgf21 deficiency markedly impaired expression of key enzymes for gluconeogenesis (Liang et al., 2014). Furthermore, we only evaluated WAT browning by FGF21 and GDF15 in vivo and hence cannot exclude indirect effects of these metabolines on metabolism. Finally, in a recent study, GDF15 was shown to be required for the effect of the hepatic sympathetic outflow on triglyceride metabolism (Luan et al., 2019); therefore, the hepatic abnormalities in the LKO mice may have altered some of the central actions of endogenous GDF15.

Resource availability
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by Minho Shong (Lead Contact and Corresponding Author; minhos@cnu.ac.kr) or Hyon-Seung Yi (Corresponding Author; jmpbooks@cnu.ac.kr).

Materials availability
This study did not generate new unique reagents.

Data and code availability
The RNA sequencing data for the liver, iWAT, GM, and hypothalamus generated during this study have been deposited in the Gene Expression Omnibus (GEO). They are available with accession number GSE149553.

METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2021.102181.

ACKNOWLEDGMENTS
This research was supported by a National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT & Future Planning (MSIP) (No. NRF-2017K1A1A203124, NRF-2017R1E1A1A01075126). H.-S.Y. was supported by the NRF, funded by the MSIP (No. NRF-2018R1C1B6004439 and NRF-2019M3E5D1A02068575) and Gilead Sciences Asia Ltd. J.H.L. was supported by the NRF, funded by the MSIP (No. 2020R1C1A1003269). J.A. was supported by grants from the École Polytechnique Fédérale de Lausanne (EPFL), the European Research Council (ERC-AdG-787702), the Swiss National Science Foundation (SNSF 31003A_179435), and a GRL grant from the National Research Foundation of Korea (NRF 2017K1A1A2013124).

AUTHOR CONTRIBUTIONS
Conceptualization: M.S., H.-S.Y., and S.G.K. Methodology: M.S., H.-S.Y., S.G.K., and M.J.C. Validation: J.Y.C. and J.T.K. Formal Analysis: M.S., H.-S.Y., S.G.K., J.T.K., and Y.E.K. Investigation: M.S., H.-S.Y., S.G.K., M.J.C., S.-B.J., H.K.C., J.Y.C., J.T.K., J.H.L., H.J.H., S.M.J., and H.J.R. Resources: M.S., H.-S.Y., S.G.K., M.J.C., and J.M.S. Writing – Original Draft: M.S., H.-S.Y., and S.G.K. Writing – Review & Editing: M.S., H.-S.Y., S.G.K., J.A., H.K., J.M.S., J.H.L., and Y.E.K. Supervision: M.S., H.-S.Y., and S.G.K. Funding Acquisition: M.S., H.-S.Y., J.A., J.M.S., H.K., and J.H.L.
DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: September 22, 2020
Revised: December 23, 2020
Accepted: February 9, 2021
Published: March 19, 2021

REFERENCES

Ameka, M., Markan, K.R., Morgan, D.A., BonDurant, L.D., Idiga, S.O., Naber, M.C., Zhu, Z., Zingman, L.V., Grobe, J.L., Rahmouni, K., et al. (2019). Liver derived FGF21 maintains core body temperature during acute cold exposure. Scientific Rep. 9, 630.

Badman, M.K., Koester, A., Flier, J.S., Kharitonenko, A., and Maratos-Flier, E. (2009). Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150, 4931–4940.

Badman, M.K., Pissios, P., Kennedy, A.R., Koukos, G., Flier, J.S., and Maratos-Flier, E. (2007). Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5, 426–437.

Bhaskaran, S., Pharaoh, G., Ranjit, R., Murphy, A., Matsuzaki, S., Nair, B.C., Forbes, B., Gispert, S., Auburger, G., Humphries, K.M., et al. (2018). Loss of mitochondrial protease ClpP protects mice from diet-induced obesity and insulin resistance. EMBO Rep. 19, e45009.

BonDurant, L.D., Ameka, M., Naber, M.C., Markan, K.R., Idiga, S.O., Acevedo, M.R., Walsh, S.A., Ornitz, D.M., and Pothoff, M.J. (2017). FGF21 regulates metabolism through adipose-dependent and -independent mechanisms. Cell Metab. 25, 935–944.e4.

Borner, T., Shaulson, E.D., Ghidewon, M.Y., Barnett, A.B., Horn, C.C., Doyle, R.P., Grill, H.J., Hawke, M.R., and De Jonghe, B.C. (2008). GDF15 induces anorexia through nausea and emesis. Cell Metab. 31, 351–362.e5.

Capogna, U., and Enríquez, J.A. (2019). The common crosstalk between mitochondria and the nucleus: what goes in between? Int. J. Biochem. Cell Biol 63, 10–15.

Chen, M.Z., Chang, J.C., Zavala-Solorio, J., Kates, L., Thai, M., Ogawara, A., Bai, X., Flanagan, S., Nunez, V., Pham, L., et al. (2017). FGF21 mimetic antibody stimulates UCp1-independent brown fat thermogenesis via FGFFR1/betaKlotho complex in non-adipocytes. Mol. Metab. 6, 1454–1467.

Cho, J., Zhang, Y., Park, S.Y., Joseph, A.M., Han, C., Park, H.J., Kalavallapalli, S., Chun, S.K., Morgan, D., Kim, J.S., et al. (2017). Mitochondrial ATP transporter depletion protects mice against liver steatosis and insulin resistance. Nat. Commun. 8, 14477.

Choi, M.J., Jung, S.B., Lee, S.E., Kang, S.G., Lee, J.H., Ryu, M.J., Chung, H.K., Chang, J.Y., Kim, Y.K., Hong, H.J., et al. (2020). An adipocyte-specific defect in oxidative phosphorylation increases systemic energy expenditure and protects against diet-induced obesity in mouse models. Diabetologia 63, 837–852.

Chrysavoroglou, K., Wang, X., Kosak, J., Lee, S.H., Kim, J.S., Foley, J.F., Travlos, G., Singh, S., Baek, S.J., and Eling, T.E. (2014). NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis, and oxidative metabolism. Int. J. Obes. 38, 1555–1564.

Chung, H.K., Kim, J.T., Kim, H.W., Kwan, M., Kim, S.Y., Shong, M., Kim, K.S., and Yi, H.S. (2017a). GDF15 deficiency exacerbates chronic alcohol-and carbon tetrachloride-induced liver injury. Scientific Rep. 7, 17238.

Chung, H.K., Ryu, D., Kim, K.S., Chang, J.Y., Kim, Y.K., Yi, H.S., Kang, S.G., Choi, M.J., Lee, S.E., Jung, S.B., et al. (2017b). Growth differentiation factor 15 is a myokine governing systemic energy homeostasis. J. Cell Biol. 216, 149–165.

Davis, R.L., Liang, C., and Sue, C.M. (2016). A factor 15 is a myomitokine governing systemic metabolic effects of GDF15. Neuron 86, 2010–2015.

De Sousa-Coelho, A.L., Maramo, P.F., and Haro, D. (2012). Activating transcription factor 4-independent induction of FGF21 during amino acid deprivation. Biochem. J. 443, 165–171.

Desai, B.N., Singhal, G., Watanabe, M., Stevanovic, D., Lundasen, T., Fisher, F.M., Mather, M.L., Vardeh, H.G., Douns, N., Adams, A.C., et al. (2017). Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury. Mol. Metab. 6, 1395–1406.

Durieux, J., Wollf, S., and Dillin, A. (2011). The cell-non-autonomous nature of electron transport chain-mediated longevity. Cell 144, 79–91.

Emmerson, P.J., Wang, F., Du, Y., Liu, Q., Pickard, R.T., Goncharz, M.D., Coskun, T., Hamang, M.J., Sindelar, D.K., Bailman, K.K., et al. (2017). Mitochondrial GDF15 deficiency exacerbates chronic alcohol-and carbon tetrachloride-induced liver injury. Nature 545, 1215–1219.

Feng, J., Bussiere, F., and Hekimi, S. (2001). Mitochondrial electron transport is a key determinant of life span in Caenorhabditis elegans. Developmental Cell 1, 633–644.

Fiorese, C.J., Schulz, A.M., Lin, Y.F., Rosin, N., Pellegrino, M.W., and Haynes, C.M. (2016). The transcription factor ATFS mediates a mammalian mitochondrial mtDNA deletion. Curr. Biol. CB 26, 2007–2014.

Forstrom, S., Jackson, C.B., Carroll, C.J., Kuronen, M., Pirinen, E., Pradhan, S., Marmyleva, A., Auranen, M., Kleine, I.M., Khan, N.A., et al. (2019). Fibroblast growth factor 21 drives dynamics of local and systemic stress responses in mitochondrial myopathy with mtDNA deletions. Cell Metab. 30, 1040–1054.e7.

Garfield, B.E., Crosby, A., Shao, D., Yang, P., Read, C., Supakak, S., Moore, S., Parfit, L., Harries, C., Rice, M., et al. (2019). Growth/differentiation factor 15 causes TGFbeta-activated kinase 1-dependent muscle atrophy in pulmonary arterial hypertension. Thorax 74, 164–176.

Hill, C.M., Laeger, T., Dehner, M., Albarado, D.C., Clarke, B., Wanders, D., Burke, S.J., Collin, J.J., Qualls-Creekmore, E., Solon-Biet, S.M., et al. (2018). Reduced body weight regulation through a brainstem-adaptive mechanism controls body weight in mice. Cell 173, 2934–2947.e3.

Houtkooper, R.H., Mouchiroud, L., Ryu, D., Moullan, N., Katsyuba, E., Knott, G., Williams, R.W., and Auwerx, J. (2013). Mitochondrial protein imbalance as a conserved longevity mechanism. Nature 497, 451–457.

Hsu, J.Y., Crawley, S., Chen, M., Ayupova, D.A., Lindhout, D.A., Higbee, J., Kutach, A., Joo, W., Gao, Z., Fu, D., et al. (2017). Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature 550, 255–259.

Inagaki, T., Dutschak, P., Zhao, G., Ding, X., Gautron, L., Parameswaran, V., Li, Y., Goertz, R., Mohammadi, M., Esser, V., et al. (2007). Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab. 5, 415–425.

Jiang, S., Yan, C., Fang, Q.C., Shao, M.L., Zhang, Y.L., Liu, Y., Deng, Y.P., Shan, B., Liu, J.Q., Li, H.T., et al. (2014). Fibroblast growth factor 21 is regulated by the IRE1alpha-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J. Biol. Chem. 289, 29751–29765.

Johnen, H., Lin, S., Kuffner, T., Brown, D.A., Tsai, V.W., Bauskin, A.R., Wu, L., Pinkhurst, G., Jiang, L., Junankar, S., et al. (2007). Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat. Med. 13, 1333–1340.

Jung, S.B., Choi, M.J., Ryu, D., Yi, H.S., Lee, S.E., Chang, J.Y., Chung, H.K., Kim, Y.K., Kang, S.G., Lee, J., and Park, J.S. (2018). Reduced respiratory capacity in macrophages results in systemic insulin resistance. Nat. Commun. 9, 1551.

Kalko, S.G., Paco, S., Jou, C., Rodriguez, M.A., Mezmaric, M., Rogac, M., Jelcovic-Vrhovek, M., Sciacco, M., Moggio, M., Fagioliari, G., et al. (2014). Transcriptomic profiling of TkJ2 deficient human skeletal muscle suggests a role for the p53
signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies. BMC Genomics 15, 91.

Khan, N.A., Nikkanen, J., Yatsuga, S., Jackson, C., Wang, L., Pradhan, S., Kivela, R., Pessia, A., Velagapudi, V., and Suomalainen, A. (2017). mTORC1 regulates mitochondrial integrated stress response and mitochondrial myopathy progression. Cell Metab. 26, 419–428.e5.

Khartonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., Sandusky, G.E., Hammond, L.J., Moyers, J.S., Owens, R.A., et al. (2005). FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627–1635.

Lee, J., Choi, J., Selén Alpergín, E.S., Zhao, H., Hartung, T., Scafi, S., Riddile, R.C., and Wolfgang, M.J. (2017). Loss of hepatic mitochondrial long-chain fatty acid oxidation confers resistance to diet-induced obesity and glucose intolerance. Cell Rep. 20, 655–667.

Lehtonen, J.M., Forstrom, S., Bottani, E., Viscomi, C., Baris, O.R., Isoniemi, H., Hockerstedt, K., Osterlund, P., Humre, M., Jylhava, J., et al. (2016). FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders. Neurology 87, 2290–2299.

Li, Z., Wang, B., Wu, X., Cheng, S.Y., Paraan, L., and Zhou, J. (2005). Identification, expression and functional characterization of the GRL gene. J. Neurochem. 93, 361–376.

Li, Q., Zhong, L., Zhang, J., Wang, Y., Bornstein, S.R., Triggle, C.R., Ding, H., LAM, K.S., and Xu, A. (2014). FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes 63, 4064–4075.

Liu, X., Jiang, N., Hughes, B., Bigras, E., Shoubridge, E., and Heikim, S. (2005). Evolutionary conservation of the clk-1-dependent mechanism of longevity: loss of mclk1 increases cellular fitness and lifespan in mice. Genes Dev. 19, 2424–2434.

Lovadi, E., Cserkezley, M., Merkli, H., FuLop, K., Sebok, A., Karczag, V., Komoly, S., and Pal, E. (2017). Elevated FGF21 in myotonic dystrophy type 1 and mitochondrial diseases. Muscle Nerve 55, 564–569.

Luan, H.H., Wang, A., Hillard, B.K., Carvalho, F., Rosenberg, A.H., Ahasic, A.M., Herzog, E.L., Kang, I., Pisan, M.A., Yu, S., et al. (2019). GDF15 is an inflammation-induced central mediator of tissue tolerance. Cell 178, 1231–1244.e11.

Markan, K.R., Nabar, M.C., Ameka, M.K., Andergord, M.D., Mangelsdorf, D.J., Klewer, S.A., Mohammad, M., and Potthoff, M.J. (2014). Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63, 4057–4063.

Markan, K.R., Nabar, M.C., Small, S.M., Peltekian, L., Kessler, R.L., and Potthoff, M.J. (2017). FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue. Mol. Metab. 6, 602–610.

Martins, R.D., Garth, G.P., Webster, T.L., Cartwright, P., Naylov, D.J., Hoj, P.B., and Hoogenraad, N.J. (1996). Selective induction of mitochondrial chaperones in response to loss of the mitochondrial genome. Eur. J. Biochem. 240, 98–103.

Michel, S., Canonne, M., Arnould, T., and Renard, P. (2015). Inhibition of mitochondrial genome expression triggers the activation of CHOP-10 by a cell signaling dependent on the integrated stress response but not the mitochondrial unfolded protein response. Mitochondrion 21, 58–68.

Montero, R., Yubero, D., Villarroya, J., Henares, D., Jou, C., Rodriguez, M.A., Ramos, F., Nascimento, A., Ortez, C.I., Campistol, J., et al. (2016). GDF-15 is elevated in children with mitochondrial diseases and is induced by mitochondrial dysfunction. PloS one 11, e0148709.

Morovat, A., Weerasinghe, G., Nesbitt, V., Hofer, M., Agnew, T., Quaghebeur, G., Sergeant, K., Fratter, C., Guha, N., Mitzikadeh, M., et al. (2017). Use of FGF-21 as a biomarker of mitochondrial disease in clinical practice. J. Clin. Med. 6, 80.

Mullican, S.E., Lin-Schmidt, X., Chin, C.N., Chavez, A., Jafar, R., Armstrong, A.A., Beck, S.C., South, V.J., Dinh, T.Q., Cash-Mason, T.D., et al. (2017). GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat. Med. 23, 1150–1157.

Ngyen, K.D., Qiu, Y., Cui, X., Goh, Y.P., Mwangi, J., David, T., Mukundan, L., Brombacher, F., Locksley, R.M., and Chawla, A. (2011). Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature 480, 104–108.

Ost, M., Coleman, V., Voigt, A., van Schothorst, E.M., Keipert, S., van der Stelt, I., Ringel, S., Graa, A., Ambrosio, T., Kipp, A.P., et al. (2016). Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action. Mol. Metab. 5, 79–90.

Ost, M., Igual Gil, C., Coleman, V., Keipert, S., Elstathou, S., Vidic, V., Weyers, M., and Klaus, S. (2020). Muscle-derived GDF15 drives diurnal amnesia and systemic metabolic remodeling during mitochondrial stress. EMBO Rep. 21, e48804.

Oussou-Ansah, E., Song, W., and Perrimon, N. (2013). Muscle mitochondria promotes longevity via systemic repression of insulin signaling. Cell 155, 699–712.

Patel, S., Alvarez-Guaita, A., Melvin, A., Rimmington, D., Dattilo, A., Miedzybrodzka, E.L., Cimino, I., Maurin, A.C., Roberts, G.P., Meek, C.L., et al. (2019). GDF15 provides an endocrine signal of nutritional stress in mice and humans. Cell Metab. 29, 707–718.e8.

Pereira, R.O., Tadina, S.M., Zasadny, F.M., Olivera, K.J., Press, K.M.P., Olivera, A., Jeffers, J., Souvenir, R., McGlaunin, R., Seel, A., et al. (2017). OPAL1 deficiency promotes secretion of FGF21 from muscle that prevents obesity and insulin resistance. EMBIO J 38, 2126–2145.

Podpisil, J.A., Knauf, C., Joza, N., Benit, P., Orthofer, M., Cani, P.D., Ebersberger, I., Nakashima, T., Sarao, R., Neely, G., et al. (2007). Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell 131, 476–491.

Potthoff, M.J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Mohammad, M., Finck, B.N., Mangelsdorf, D.J., Klewer, S.A., et al. (2009). FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl. Acad. Sci. United States America 106, 10853–10858.

Quiros, P.M., Mottis, A., and Auwerx, J. (2016). Mitochondrial communication: heat, mitochondria and stress. Nat. Rev. Mol. Cell. Biol. 17, 213–226.

Quiros, P.M., Prado, M.A., Zamboni, N., D’Amico, D., Williams, R.W., Finley, D., Gygi, S.P., and
Auwerx, J. (2017). Multi-omics analysis identifies ATF4 as a key regulator of the mitochondrial stress response in mammals. J. Cel. Biol. 216, 2027–2045.

Schaum, N., Lehallier, B., Hahn, O., Hosseinzadeh, S., Lee, S.E., Sit, R., Lee, D.P., Losada, P.M., Zardeneta, M.E., and Pálovics, R. (2019). The murine transcriptome reveals global aging nodes with organ-specific phase and amplitude. bioRxiv. https://doi.org/10.1101/662254.

Sorrentino, V., Menzies, K.J., and Auwerx, J. (2018). Repairing mitochondrial dysfunction in disease. Annu. Rev. Pharmacol. Toxicol. 58, 353–389.

Tsai, V.W., Manandhar, R., Jorgensen, S.B., Lee-Ng, K.K., Zhang, H.P., Wu, L., Marquis, C.P., et al. (2013). TGF-β superfamily cytokine MIC-1/GDF15 is a physiological appetite and body weight regulator. PloS one 8, e55174.

Tsai, V.W., Manandhar, R., Jorgensen, S.B., Lee-Ng, K.K., Zhang, H.P., Wu, L., Marquis, C.P., Jiang, L., Husami, Y., Lin, S., Sainsbury, A., et al. (2014). The anorectic actions of the TGFβ superfamily cytokine MIC-1/GDF15 require an intact brainstem area postrema and nucleus of the solitary tract. PloS one 9, e100370.

Tschop, M.H., Speakman, J.R., Arch, J.R., Auwerx, J., Bruning, J.C., Chan, L., Eckel, R.H., Farese, R.V., Jr., Galgani, J.E., Hambly, C., et al. (2011). A guide to analysis of mouse energy metabolism. Nat. Methods 9, 57–63.

Veniant, M.M., Sivitz, G., Helmering, J., Komorowski, R., Lee, J., Fan, W., Moyer, C., and Lloyd, D.J. (2015). Pharmacologic effects of FGF21 are independent of the “browning” of white adipose tissue. Cell Metab. 21, 731–738.

Villarroya, J., Gallego-Escuredo, J.M., Delgado-Angles, A., Cairo, M., Moure, R, Gracia Mateo, M., Domingo, J.C., Domingo, P., Giralt, M., and Villarroya, F. (2018). Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue. Aging cell 17, e12822.

von Holstein-Rathlou, S., BonDurant, L.D., Peltekian, L., Naber, M.C., Yin, T.C., Claflin, K.E., Unzar, A.I., Madsen, A.N., Ratner, C., Holst, B., et al. (2016). FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver. Cell Metab. 23, 335–343.

Xu, J., Lloyd, D.J., Hale, C., Stanislaus, S., Chen, M., Sivitz, G., Vonderfecht, S., Hecht, R., Li, Y.S., Lindberg, R.A., et al. (2009). Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250–259.

Yang, L., Chang, C.C., Sun, Z., Madsen, D., Zhu, H., Padlaijer, S.B., Wu, X., Huang, T., Hultman, K., Paulsen, S.J., et al. (2017). GPRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat. Med. 23, 1158–1166.

Yatsuga, S., Fujita, Y., Ishii, A., Fukumoto, Y., Arakawa, H., Kakuma, T., Kojima, T., Ito, M., Tanaka, M., Saiki, R., et al. (2015). Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann. Neurol. 78, 814–823.

Zhang, M., Sun, W., Qian, J., and Tang, Y. (2018). Fasting exacerbates hepatic growth differentiation factor 15 to promote fatty acid beta-oxidation and ketogenesis via activating XBP1 signaling in liver. Redox Biol. 16, 87–96.

Zhao, Q., Wang, J., Levichkin, I.V., Stasinopoulos, S., Ryan, M.T., and Hoogemars, N.J. (2003). A mitochondrial specific stress response in mammalian cells. EMBO J. 21, 4411–4419.
Supplemental information

Differential roles of GDF15 and FGF21 in systemic metabolic adaptation to the mitochondrial integrated stress response

Seul Gi Kang, Min Jeong Choi, Saet-Byel Jung, Hyo Kyun Chung, Joon Young Chang, Jung Tae Kim, Yea Eun Kang, Ju Hee Lee, Hyun Jung Hong, Sang Mi Jun, Hyun-Joo Ro, Jae Myoung Suh, Hail Kim, Johan Auwerx, Hyon-Seung Yi, and Minho Shong
**Transparent Methods**

**Mice**

All the experiments were performed in homozygous male mice. Liver-specific *Crif1*-deleted mice (LKO) were generated by crossing Albumin-Cre transgenic mice and floxed- *Crif1* mice (*Crif1*<sup>fl/fl</sup>, control). Albumin-Cre mice were purchased from the Jackson Laboratory (Tg[Alb-Cre]21Mgn) and had been backcrossed on to the C57BL/6J background, and floxed- *Crif1* mice were generated as previously described (Kwon et al., 2008). GDF15 null mice (*Gdf15<sup>−/−</sup>*, GKO) and FGF21 null mice (*Fgf21<sup>−/−</sup>*, FKO) were kindly provided by Dr. S. Lee (Johns Hopkins University School of Medicine, Baltimore, MD) and Dr. N. Itoh (Kyoto University Graduate School of Pharmaceutical Sciences), respectively. These null mice were crossed with floxed- *Crif1* and Albumin-Cre transgenic mice to generate LGKO (LKO/*Gdf15<sup>−/−</sup>*<sup>−/−</sup>) and LFKO (LKO/*Fgf21<sup>−/−</sup>*<sup>−/−</sup>), respectively. The mice were housed in a specific pathogen-free facility at the Preclinical Research Centre of Chungnam National University Hospital (CNUH-019-A0077) under a 12 h light/12 h dark cycle, at an ambient temperature of 22±2 °C and at a relative humidity of 40–60%. They were fed a chow diet (Teklad global 18% protein, 2918C, ENVIGO) and used in the experiments at 8–10 weeks of age. Diet-induced obesity (DIO) was induced by feeding an HFD (60% of total energy intake as fat, TD.06414, ENVIGO) for 8 weeks, starting at 6 weeks of age. All the experimental procedures complied with the guidelines of and were approved by the Institutional Animal Care and Use Committees.

**Primary hepatocyte isolation and culture**

As previously described (Kang et al., 2017; Yi et al., 2014), *in situ* perfusion was conducted in control and LKO mice for the isolation of primary hepatocytes using EGTA solution (0.5 mM EGTA, 25 mM Tricine, 5.4 mM KCl, 0.44 mM KH<sub>2</sub>PO<sub>4</sub>, 140 mM NaCl, 0.34 mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.2) and collagenase solution (0.8 mg/ml collagenase type I in Hank’s Balanced Salt Solution; Worthington, Freehold, NJ, USA) for 30 min. The suspensions were then filtered using 70 μm cell strainers (BD Falcon, Millville, NJ, USA) and centrifuged at 1,000 × *g* for 5 min. The pelleted cells were resuspended and isolated with 40% Percoll solution (GE Healthcare, Buckingham, UK) at 1,200 × *g* for 10 min at 4°C, and the isolated primary hepatocytes were seeded in Medium 199 (Sigma
Aldrich, MO, USA) containing 10% foetal bovine serum (Thermo Fisher Scientific, Waltham, MA, USA) and 1% penicillin and streptomycin (Welgene, Daegu, South Korea) at a density of $3 \times 10^5$ cells per well.

**Blue native polyacrylamide gel electrophoresis (BN-PAGE)**

For the mitochondrial isolation, 30 mg of liver tissue were homogenized in isolation buffer (210 nM mannitol, 70 mM sucrose, 1 mM EGTA, 5 mM HEPES, pH 7.2) using WiseStir (HS-30E, Daihan, Wonju, South Korea). The samples were then centrifuged at $600 \times g$ for 10 min at 4°C and the supernatants were re-centrifuged at $17,000 \times g$ for 10 min at 4°C. The pelleted mitochondria were resuspended and the constituent proteins separated using a Native PAGE Novex Bis-Tris Gel system (Invitrogen). To quantify the mitochondrial OxPhos complexes, 30 μg of each mitochondrial fraction in Native PAGE sample buffer (Invitrogen) and 10% n-dodecyl-β-D-maltoside were loaded onto Native PAGE 3–12% Bis-Tris gels. After electrophoresis, the separated proteins were transferred to PVDF membranes using iBlot gel transfer stacks (Invitrogen) and fixed in 8% (v/v) acetic acid. After overnight drying, the membranes were incubated with anti-OxPhos complex cocktail (#457999, Invitrogen; sc-58347, Santa Cruz) for 90 min and visualized using a Western Breeze Chromogenic Western Blot Immuno-detection kit (Invitrogen).

**Oxygen consumption rate**

The mitochondrial OCR and extracellular acidification rate (ECAR) were measured using a Seahorse XF-24 extracellular flux analyzer (Seahorse Bioscience, North Billerica, MA, USA). Primary hepatocytes were isolated and cultured overnight at a concentration of $1 \times 10^4$ cells per well on Seahorse XF-24 plates. The calibration cartridge (#102416-100, Seahorse Bioscience) was hydrated using calibration buffer (#100840-000, Seahorse Bioscience) 1 day prior to the analysis and incubated at 37°C in a non-CO$_2$-containing incubator. The cells were then washed and incubated in XF Assay medium lacking sodium bicarbonate (#102365-100, Seahorse Bioscience) at 37°C in a non-CO$_2$-containing incubator for 1 h. The calibration plate was then loaded into the Seahorse XF-24 analyzer and calibration was performed for 30 min at 37°C. The OCR and ECAR were then analyzed at baseline and following the addition of three mitochondrial inhibitors: oligomycin (2 μg/ml), CCCP
(10 μM) and rotenone (1 μM). The measurements were programmed for four cycles of 2 min of mixing, 2 min of waiting and 3 min of measurement at both baseline and following the addition of each inhibitor.

**Glycolysis assay**

Glycolysis was assessed in primary hepatocytes by measuring the ECAR using a Seahorse XF Glycolysis Stress Test Kit (#103020-100, Seahorse Bioscience) and the Seahorse XF-24 extracellular flux analyzer. Primary hepatocytes were seeded at a concentration of $1 \times 10^4$ cells per well in Seahorse XF Culture Microplates. The calibration cartridge was hydrated at 37°C in a non-CO$_2$-containing incubator 1 day before the assay. The growth medium was replaced with Seahorse XF Base Medium (#103193-100, Seahorse Bioscience) containing glutamine (1 mM) and the cells were incubated at 37°C in a non-CO$_2$-containing incubator for 1 hour. To measure the ECAR, three reagents were used: glucose (10 mM), oligomycin (1 μM) and 2-deoxyglucose (50 mM). These measurements were conducted over three cycles of 2 min of mixing, 2 min of waiting and 3 min of measurement at baseline and following the addition of each chemical.

**Transmission electron microscopy**

The livers of control and LKO mice were cut into 1 mm$^3$ specimens and pre-fixed with 2.5% glutaraldehyde in pH 7.4 phosphate buffer (0.1 M) overnight at 4°C. The specimens were then washed in phosphate buffer three times for 10 min, which was followed by post-fixation using 1% osmium tetroxide (0.1 M) in phosphate buffer for 1 h at 4°C. After dehydration in a graded series of ethanol mixtures (50%, 75%, 90%, 95% and 100%), the ethanol were replaced by propylene oxide and mixtures of Embed 912 resin (EMS). After embedding and polymerization in fresh resin for 24 hours, the blocks were sectioned at 80 nm on an ultramicrotome (Leica, Bensheim) using a diamond knife and mounted on 200-mesh copper grids. The sections were then stained with uranyl acetate and lead citrate, and examined using a Leo912 transmission electron microscope (Carl Zeiss, Oberkochen) at 120 kV.

**Quantitative real-time PCR (QPCR)**
Tissues were homogenized using a TissueLyser II (Qiagen) and RNA was isolated using TRIZol™ Reagent (15596018, Life Technologies, Thermo Fisher Scientific). cDNA was synthesized from the RNA (5 μg) using Oligo(dT)15 Primer (Promega) and M-MLV Reverse Transcriptase (Thermo Fisher Scientific). QPCR was performed using a 7500 Fast Real-Time PCR System (Applied Biosystems, Carlsbad, CA) and GoTaq qPCR Master Mix (BRYT Green, Promega). Relative quantification was performed using Applied Biosystems 7500 Software (ver. 2.0.6) and the ΔΔCT method, and gene expression was normalized to that of 18s rRNA. The primers used are listed in Table S1.

Glucose uptake assay

Isolated primary hepatocytes were seeded at a density of $1 \times 10^5$ cells per well in a sterile 96-well plate and incubated for 24 h before the assay. The cells were serum-starved for 2 h and incubated in 2% BSA/KPRH buffer (20 mM HEPES, 5 mM KH$_2$PO$_4$, 1 mM MgSO$_4$, 1 mM CaCl$_2$, 136 mM NaCl, 4.7 mM KCl, pH 7.4) for 40 min. Some of the wells were treated with insulin (1 μM, I9278, Sigma Aldrich) in KPRH buffer for 20 min. Glucose uptake was measured using 2-DG and a Glucose uptake assay kit (ab 136955, Abcam, Cambridge, UK), according to the manufacturer's instructions. Glucose uptake was calculated according to the colorimetric change, which was measured using a microplate reader (VersaMax, Molecular Devices) at 412 nM at 2 min intervals.

Western blotting

Mouse tissues were homogenized using a TissueLyser II in lysis buffer (50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 1 mM EDTA, pH 8.0; 0.1% Triton X-100) containing a protease inhibitor cocktail (#11836145001, Roche, Basel, Switzerland) and phosphatase inhibitors (04906837001, Roche) on ice for 30 min. After centrifugation at 16,000 g for 15 min, the protein concentrations of the supernatants were measured using a BCA protein assay (#23227, Thermo Fisher Scientific). Fifty micrograms of protein per sample were loaded onto 8–12% polyacrylamide gels and electrophoresis was performed. The separated proteins were then electrotransferred to 0.45 μm PVDF membranes (# IPVH00010, Millipore) at 200 mA for 2 h. Membranes were blocked with 5% skimmed milk (#T145.2, Roth) in TBS/T buffer (20 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.6) for 1 h and
then incubated with primary antibodies overnight at 4°C. After washing three times with TBS/T, the membranes were incubated with secondary antibodies for 1 h at room temperature and then visualized using ECL solution (#34580, Thermo Fisher Scientific). Target protein levels were normalized to those of β-actin, α-tubulin or glyceraldehyde 3-phosphate. The antibodies used are listed in Table S4.

Hematoxylin and eosin (H&E) staining

Liver, iWAT and BAT samples were obtained from male control, LKO, GKO, LGKO, FKO and LFKO mice that had been fed a chow or HFD (60% fat) for 8 weeks. The tissues were fixed in 10% neutral formalin (BBC Biochemical, Mt. Vernon, WA, USA) overnight and then embedded in paraffin wax. After sectioning (4 μm thickness), the tissue samples were deparaffinized by three immersions in xylene for 4 min each and washed with a graded ethanol series for 2 min each. After washing with distilled water for 4 min, the tissue sections were stained with hematoxylin (S2-5, YD Diagnostics, Yongin, South Korea) for 4 min and eosin (#HT1101128, Sigma Aldrich) for 3 min. The sections were then dehydrated with a graded ethanol series for 2 min each and immersed three times in xylene for 4 min each, and then mounted and examined using an upright microscope (#BX53, Olympus, Tokyo, Japan).

Glucose tolerance and insulin tolerance testing

For glucose (GTT) and insulin (ITT) tolerance testing, mice were fasted for 6 h from 08:00 to 14:00. GTT was conducted by the intraperitoneal injection of 2 g/kg glucose (dextrose, Choongwae) in chow diet-fed mice or 1 g/kg glucose in HFD-fed mice. For ITT, mice were injected intraperitoneally with 0.75 U/kg insulin (Humalog, Lilly, Indianapolis, IN, USA). After each injection, the glucose concentrations of tail vein blood were measured after 0, 15, 30, 60, 90 and 120 min using a glucometer (Accu-Chek Active, Roche).

Serum biochemical measurements

Blood was collected from a retro-orbital sinus, incubated at room temperature for 2 h and then centrifuged at 600 g for 5 min to obtain serum. Serum triglyceride, cholesterol, GOT/AST and GPT/ALT (#1650, #1450,
#3150, #3250, Fujifilm) were measured using a Fuji DRI-CHEM 7000i (Fujifilm, Tokyo, Japan). The insulin (80-INSMSU-E01, Alpco), GDF15 (MGD150, R&D Systems, Minneapolis, MN, USA), FGF21 (MF2100, R&D Systems), leptin (MOB00, R&D Systems), lactate (#K607-100, Bio Vision, Milpitas, CA, USA) and β-hydroxybutyrate (Free Style Optium H β-Ketone, Abbott, Illinois, USA) concentrations were determined in serum.

**Body composition and indirect calorimetry**

Lean body mass (LBM) and fat mass (FM) were measured by dual energy X-ray absorptiometry (DXA) (Medikors, Seongnam, South Korea) in control, LKO, GKO, LGKO, FKO and LFKO mice fed a chow diet or an HFD (60% fat). The total body, lean and fat masses were automatically quantified using InAlyzer (ver. 1.00). EE was measured by indirect calorimetry. Before this measurement, the mice were placed in individual metabolic cages and acclimatized for 2 days. Oxygen consumption (VO$_2$), carbon dioxide production (VCO$_2$), EE, respiratory exchange rate (RER), physical activity and food intake were measured every 3 minutes using an OxyletProTM system (Panlab, Barcelona, Spain). The mean values for the daytime (from 08:00 to 18:00) and night-time (from 18:00 to 08:00) were calculated using METABOLISM software (ver. 2.2, Panlab).

**RNA sequencing**

RNA was isolated from the liver, iWAT, GM and hypothalamus of 8-week-old control and LKO mice. To construct cDNA libraries, 1 μg RNA and a TruSeq RNA Library Prep Kit v2 (RS-122-2001, Illumina, San Diego, CA, USA) were used, and the results were quantified by QPCR using an 2100 Bioanalyzer (Agilent Technology Inc., Santa Clara, CA, USA). The libraries were used for 100 nt paired-end sequencing by an Illumina HiSeq4000 (Illumina). After removing the low-quality and adapter sequences using Trimmomatic, the reads were aligned with the *Mus musculus* genome (mm10) using HISAT (ver. 2.0.5) (Kim et al., 2015). Two types of indexes were used for alignment (a global, whole-genome index and tens of thousands of small local indexes), which were downloaded from the UCSC table browser (http://genome.uscs.edu). StringTie (ver. 1.3.3b) was used to assemble the transcript, and provided the relative abundance estimates as fragments per kilobase of exon per million fragments mapped (FPKM) values of the transcript or gene. After excluding the genes with
one more than zero FPKM values, the signal value (FPKM+1) was transformed to a base 2 logarithm and normalized by quantile normalization methods to reduce the systematic bias. These values were used for the analysis of the differential expressed genes (DEGs) in the mouse groups. The statistical significance of the DEG values was calculated using independent t-tests ($p<0.05$) and fold change ($|FC|\geq2$). The false discovery rate (FDR), which estimates the frequency of type I statistical errors, was determined by adjusting the $p$-value using the Benjamini and Hochberg algorithm.

**Bioinformatic analysis**

Transcriptome data for the liver, iWAT and GM were used for bioinformatic analysis. The Database for Annotation, Visualization and Integrated Discovery (DAVID ver. 6.8, https://david.ncifcrf.gov) (Huang da et al., 2009) was used to functionally annotate the data. The transcripts that satisfied the $|FC|\geq2$ and $p<0.05$ criteria were matched with Entrez IDs to identify up- and downregulated genes. GOTERM_BP, which is based on Gene Ontology, and KEGG_PATHWAYS (Kyoto Encyclopaedia of Genes and Genomes) were used as the annotation categories. Gene Set Enrichment Analysis (GSEA) was performed in the liver transcriptome using GSEA v4.1.0, as described previously (Mootha et al., 2003; Subramanian et al., 2005). Gene sets including C2 KEGG subset (186 gene sets) and C2 REACTOME subset (1532 gene sets) of canonical pathways were downloaded from the Molecular Signatures Database (MSigDB, http://software.broadinstitute.org/gsea). For the graphical analysis of the transcriptome, PermutMatrix (ver. 1.9.3) and Network2Canvas were used, as previously described (Caraux and Pinloche, 2005; Tan et al., 2013). For hierarchical clustering and the identification of network nodes, the normalized z-score, based on the FPKM of the transcriptome, was used and is visualized using a gradation of colors. Proteins secreted by the liver were classified using the PANTHER classification system (v.14.0) (Mi et al., 2013).

**Quantification and statistical analysis**

Statistical analyses were performed using IBM SPSS Statistics software (ver. 24, IBM, Armonk, NY, USA). Data are presented as means ± standard errors of the mean (SEMs). All the experimental data were analyzed using Student’s two-tailed $t$-test, one-way ANOVA followed by Scheff’s *post-hoc* test or analysis of covariance.
(ANCOVA) with the covariate of total body mass. $P < 0.05$ was considered to represent statistical significance. The number of biological replicates ($n$), the number of independent experiments and the method of statistical analysis used are reported in the corresponding figure legends.
**Supplemental Information**

**Figure S1.** Liver-specific *Crif1*-deficient mice exhibit infiltration of mononuclear cells in the liver (Related to Figure 1).

(A) Schematic illustration of the deletion of exon2 of the *Crif1* allele on chromosome 8 through the crossing of *Crif1*loxp/loxp mice and Albumin-Cre transgenic mice.

(B) Quantitative PCR analysis of *Crif1* mRNA expression in the liver, eWAT, BAT and gastrocnemius muscle (GM) of control (Ctrl) and LKO mice (n=3 biological replicates from two independent experiments).

(C) Representative haematoxylin and eosin-stained liver sections from Ctrl and LKO mice at 10 weeks of age.
(n=4 biological replicates from two independent experiments). The yellow arrows indicate mononuclear cells in the liver.

(D) Serum ALT and AST activities in Ctrl and LKO mice at 11 weeks of age (n = 4 biological replicates from three independent experiments).

(E) FACS analysis of infiltrated monocytes (IM, F4/80\textsuperscript{low}CD11b\textsuperscript{high}), kupffer cells (KCs, F4/80\textsuperscript{high}CD11b\textsuperscript{low}), neutrophils (CD11b\textsuperscript{high}Ly6G\textsuperscript{high}), inflammatory monocyte (CD11b\textsuperscript{high}Ly6C\textsuperscript{high}), and Treg cells (CD4\textsuperscript{high}CD44\textsuperscript{high}CD62L\textsuperscript{high}) in liver of control and LKO mice at 8 weeks of age (n=4 per group).

(F) Western blot analysis of apoptotic markers in the livers of Ctrl and LKO mice at 10 weeks of age (n=3 biological replicates, left). The results of one representative experiment of the two performed is shown. The relative band densities of cleaved caspase 3 and PARP1 in the liver (right). There were no significant differences. The mice were fed a chow diet (6% fat). Data are mean ± SEM and were analysed using Student’s t-test (*p<0.05 vs. Ctrl).
Figure S2. Liver-specific Crif1-deficient mice have low fat mass and high insulin sensitivity when consuming a chow diet and high-fat diet (Related to Figure 2).

Mice fed a chow diet were used in (A-I) and mice fed an HFD for 8 weeks were used in (J-Q).

(A) Tissue mass per unit body mass in Ctrl and LKO mice (n=5 biological replicates from three independent experiments).

(B) Quantitative PCR analysis of the expression of genes involved in gluconeogenesis in Ctrl and LKO livers (n=5–6 biological replicates from two independent experiments). Mice were fasted for 6 hours.
(C) HOMA-IR, calculated using the serum insulin and glucose concentrations of Ctrl and LKO mice (n=12 biological replicates).

(D and E) Serum triglyceride (D) and total cholesterol (E) in Ctrl and LKO mice (n=6 biological replicates from two independent experiments).

(F) Physical activity, assessed using the locomotor activity count in Ctrl and LKO mice housed in individual cages (n=7–8 biological replicates).

(G) Body surface temperature, measured using an infrared thermometer, in Ctrl and LKO mice (n=7 or 10 biological replicates from two independent experiments).

(H) RQ in mice fed a chow diet (n=7–8 biological replicates).

(I) Serum β-hydroxybutyrate in Ctrl and LKO mice that had been fasted for 16 hours (n=7 or 11 biological replicates).

(J) Tissue masses in Ctrl and LKO mice fed a high-fat diet (n=8 biological replicates from two independent experiments).

(K-M) Blood glucose (K), serum insulin (L) and HOMA-IR (M) in 6 h-fasted Ctrl and LKO mice fed a high-fat diet (n=4 biological replicates).

(N and O) Serum triglyceride (N) and total cholesterol (O) of Ctrl and LKO mice fed a high-fat diet (n=4 biological replicates).

(P) RQ of Ctrl and LKO mice, fed a high-fat diet, at 14 weeks of age (n= 6 or 8 biological replicates).

(Q) Serum β-hydroxybutyrate of Ctrl and LKO mice, fed a high-fat diet, at 14 weeks of age (n=8 biological replicates). Mice were fasted for 18 h before the measurement. Data are mean ± SEM and were analysed using Student's t-test (*p<0.05, **p<0.01, ***p<0.001 vs. Ctrl).
Figure S3. Liver-specific *Crif1*-deficient mice exhibit normal insulin signalling and normal mRNA expression of fatty acid metabolic genes in GM and BAT (Related to Figure 3).

(A and B) Western blot analysis of AKT phosphorylation in the GM (A) and BAT (B) of Ctrl and LKO mice at 9 weeks of age (n=3 biological replicates). Mice were fasted for 6 h and then insulin was administered intraperitoneally (4 U/kg).

(C) Quantitative PCR analysis of *Glut1* and *Glut4* mRNA expression in the eWAT, BAT and GM of Ctrl and LKO mice at 9 weeks of age (n=6 biological replicates from two independent experiments).

(D) Quantitative PCR analysis of fatty acid oxidation gene expression in the eWAT, BAT and GM from Ctrl and LKO mice at 9 weeks of age (n=5–6 biological replicates from two independent experiments). Data are expressed as the mean ± SEM and were analysed using two-way ANOVA followed by Scheff’s *post-hoc* test in (A) and (B), and Student’s *t*-test in (C) and (D) (*p<0.05 vs. Ctrl).
Figure S4. RNA sequencing suggests the downregulated lipid metabolism in the liver of LKO mice (Related to Figure 4).

(A) Venn diagram of the differentially expressed genes (DEGs) obtained from RNA sequencing in the liver, iWAT, GM and hypothalamus of mice (n=3 biological replicates). The numbers represent the differentially expressed transcripts in LKO mice, compared with Ctrl mice (fold difference ≥ ±1.5-fold, p < 0.05).

(B) Volcano plot showing the DEGs in GM (left panel) and hypothalamus (right panel) of LKO mice compared with controls. The colored dots indicate the DEGs with ≥ ±1.5-fold difference from Ctrl mice. The red and blue
dots indicate the upregulated and downregulated transcripts, respectively.

(C) Top-ranked functional annotation chart for the liver, using DEGs (DEGs; ≥ ±1.5-fold difference from Ctrl). Functional annotation was categorised using the KEGG pathway in DAVID (ver.6.8) and ordered according to gene number.

(D) Heat map showing the DEGs termed as 'Upregulation-Metabolic pathways’ in (C).

(E) Heat map showing the differentially expressed transcription factors that regulate glucose and lipid metabolism (downregulation) and the cellular stress response (upregulation) in the livers of Ctrl and LKO mice (n=3 biological replicates). The data in (C) were analysed using a modified Fisher’s Exact p-value (*p<0.05, **p<0.01, ***p<0.001).
Figure S5. LGKO and LFKO mice were generated by crossing LKO and global GKO (Gdf1−/−) and LKO and global FKO (Fgf21−/−) mice, respectively (Related to Figure 5).

(A) PCR genotyping results for control mice (Ctrl, Crif1f/f), liver-specific Crif1-null mice (LKO, Crif1f/f, Alb−), global Gdf15-null mice (GKO, Gdf15−/−) and liver-specific Crif1- and global Gdf15-null mice (LGKO, Crif1f/f, Alb−/Gdf15−/−). The PCR bands show the DNA amplification of Cre (565 bp), Crif1 (Crif1-WT, 171 bp; Crif1-loxp, 205 bp) and Gdf15 (Gdf15-WT, 228 bp; Gdf15-KO, 598 bp).

(B) PCR genotyping results for control mice (Ctrl, Crif1f/f), liver-specific Crif1-null mice (LKO, Crif1f/f, Alb−), global Fgf21-null mice (FKO, Fgf21−/−), and liver-specific Crif1- and global Fgf21-null mice (LFKO, Crif1f/f, Alb−/Fgf21−/−). The PCR bands show the DNA amplification of Cre (565 bp), Crif1 (Crif1-WT, 171 bp; Crif1-loxp, 205 bp) and Fgf21 (Fgf21-WT, 540 bp; Fgf21-KO, 240 bp).

(C and D) Quantitative PCR analysis of Crif1 and Gdf15 mRNA expression (C), and Crif1 and Fgf21 mRNA expression (D) in the liver of mice (n=6 biological replicates).

(E and F) Serum GDF15 protein (E) and FGF21 protein (F) in Ctrl, LKO, GKO, LGKO, FKO and LFKO mice.
(n=4–7 biological replicates from two independent experiments).

The mice were studied at 8–9 weeks of age and fed a chow diet. Data in (C-F) are mean ± SEM. Statistical analyses were performed using ANOVA followed by Scheff's post-hoc test in (C-F) (*p<0.05, **p<0.01, ***p<0.001 vs. Ctrl).
Figure S6. Genetic ablation of *Gdf15* and *Fgf21* in LKO mice attenuated the phosphorylation of AKT after insulin stimulation (Related to Figure 6).

(A) Relative band of phosphorylation of AKT at Thr308 (left panel) and Ser473 (right panel) in iWAT of Ctrl, LKO, GKO, LGKO mice fed a chow diet. Mice were fasted for 6 h and then administered intraperitoneally with insulin (4 U/kg).

(B) Relative band of phosphorylation of AKT at Thr308 (left panel) and Ser473 (right panel) in iWAT of Ctrl, LKO, FKO, LFKO mice fed a chow diet. Mice were fasted for 6 h and then administered intraperitoneally with insulin (4 U/kg). One representative experiment of the two conducted is shown. As less biological replicates within the group, statistical analysis were not conducted.
### Table S1. Primers used for the quantitative PCR analysis of mRNA expression in mice

| Gene      | Forward (5’→3’)                        | Reverse (5’→3’)                        |
|-----------|----------------------------------------|----------------------------------------|
| Acadm     | TGACGGAGCAGGCAATGA                      | TCGTCAACCTTCTTCTCTGCTT                |
| Acadvl    | TTACATGCTGAGTGCCAACATG                  | CGCCTCCGAGCAGAAAGATT                  |
| Aco       | ATGACCCCACCTCTGACAC                     | GAAGGTCAGCCACCATGATT                  |
| Adipoq    | TCTCCTGGTCTCTTTAATCCTGCC               | CATCTCCTTCTCTCCCTCTCTCTCC            |
| Atf3      | TGCCTGCAAGAAGAGTGCAAGA                 | CCTTCAGCTCAGCATTCAA                  |
| Atf4      | GGTTCTGTCTCTCCACTCCA                   | AAGCAGCAGAGTCAGGCTTTTC               |
| Atf5      | TGGGCTGGCTGTAGACTAT                     | GTCATCAATGAGAAGGCC                  |
| Atp23     | GACTGCTCCCTTGTGAAGCA                   | CGCAGCAGAAGTCGATG                   |
| Atp5a     | AGGCTATCTCTGTGTATGTG                    | CTTCATGATCTTGCCACCT                  |
| Cd36      | TGCTGGAGCTGTATTGGT                      | TGGGTTTGACAATCAGA                    |
| Chop (Ddit3) | CCACCACACCTGAAAGCAGAA                  | AGGTGAAGGGCGAGAAGGACTCA              |
| Clpp      | GCCATTCACTGGCCAATCC                    | TGCTGACTCGATCACCTGTAG                |
| Cpt1a     | TATAACAGGTCGTTTGAC                     | CAGAGTGCCCAAATGATG                   |
| Cpt1b     | TCGCAGGAGAAACACCATGT                   | AACAGTGCTGTGGCGGATG                   |
| Crif1     | GAACGCTGGGAGAATAATTCA                  | ATAGTTCCCTGGAAGCGAGCA                |
| Fasn      | CCCCCATGAGAGGGATCA                     | ACTCCACAGGTTGGGAACAAG                |
| Fgf21     | AGATCAGGGAGGATGGACA                    | TCAAAGTGAGGCGATCCATA                 |
| Fgfr1c    | CCGTATGCAGATCTCTGAAGA                  | GATAGAGTTACCCCGCAAGCA                |
| G6pase    | TCTGTCCCGGATCTACCTTG                   | GTAGAATCCAAGGGGAAAC                  |
| Gck       | CCCAGAAGGCTCAGAAGTTG                   | GCATCAC CCTGAAGTGGTT                |
| Gdf15     | GAGCTACGGGGTGCTGCTTC                   | GGGACCGCAATCTCACCT                  |
| Glut1     | GCCCCCAGAGGTTATTTGA                    | CGTGTTGAGTGTTG                   |
| Glut2     | GGCTATTCTCAGGACTGTTTT                  | TTTCTTGCCCTGACTTCT                   |
| Glut4     | TGATTCTGCTGCCCTCTGT                    | GGACATTGGACGCTCTCTCT                 |
| Grp78     | GTGTGTGAGACCAAGGATGTG                  | AGTCAGGCAAGGAGTCTTAGG               |
| Hspd1     | GAGCTGGGTCCCTACCTCG                    | AGTCAGGCAAGGATCTTCTCGG              |
| Gene          | Forward Sequence | Reverse Sequence |
|--------------|------------------|------------------|
| Htra2        | TCCCCGGAGCCAGTACAAT | GAAAGGGTGCCGGTCTAGGG |
| Immp1l       | ATGACCCATGCACGCTTTGA | TCTGCTACCACAGCCATAA |
| Immp2l       | ACATGTGGGTTGAAGCGAT | CCCAGAGAAACCGGTCCAAA |
| Klb (βKlotho) | GGAGGAGACCGTAAAATCGGGCTTA | ACGACCCGACGAGGCTGTT |
| Lonp1        | AGCCCTATGTTGGCCTTTCC | CCGGCTGATGGTAATCCTTCT |
| Pepck        | GCATAACTAACCCGAGGCAAAG | CATCCAGGCAATGTACGCTC |
| Pgc1α        | TCACACCAAACCCACAGAAA | CTTGGGGTCATTGTTGGACT |
| Ppara        | AGAAGTTGCAAGAGGGGAATT | TTGAAGGAGCTTTGGAAGAA |
| Pparγ        | TGCGAGCTCAGCTGAATCAAC | ACGTGCCTGTCGACGATCTG |
| SpXbp1       | CTAGGTCGGAATCGGATGAG | GTCATGGGAAGATTTGCTGG |
| Srebp1       | AAAAAAAAAAACAACAACTAAGTCT | GTCAGTGTGTCCTCCACCTCAGT |
| Srebp1a      | GCGCCATGGAGAGCTG | TTGGCACCTGGGCTGCT |
| Srebp1c      | ATCGCAAACAAAGCTGACCTG | AGATCCAGGTGGTAGG |
| Srebp2       | CAGAGCTTAAAGGACATCG | CACAAAGACGCTACAGGACAA |
| Tffam        | TAGGCACCAATTTAGCGTGAG | CAGACAAGACGTGATAGACGAGG |
| Tid1         | GGAAGCAAGGATAGGCGAGA | GTTGACCGCTTTTCCTCACGAC |
| Ucp1         | CACCTTCCCGCTGGACACT | CCCTAGGACACCTTTATACCTAATG |
| Usp30        | ACAAGCCCCTTTCTCCGCTT | GAACCTGGGAGTGATCGGTG |
| Name                        | Source          | Identifier                                      |
|-----------------------------|-----------------|-------------------------------------------------|
| anti-CRIF1                  | Santa Cruz      | Cat# sc-374122; RRID:AB_10917749                |
| anti-NDUFA9                 | Abcam           | Cat# ab14713; RRID:AB_301431                    |
| anti-SDHA                   | Cell Signaling  | Cat# 5839S; RRID:AB_10707493                   |
| anti-UQCRC2                 | Abcam           | Cat# ab14745; RRID:AB_2213640                   |
| anti-COX4                   | Santa Cruz      | Cat# sc-58348; RRID:AB_2229944                  |
| anti-ATP5A                  | Invitrogen      | Cat# 459240; RRID:AB_2532234                   |
| anti-TOM20 (FL-145)         | Santa Cruz      | Cat# sc-11415; RRID:AB_2533834                  |
| anti-β-actin                | Sigma Aldrich   | Cat # A2066; RRID:AB_476693                    |
| anti-OxPhos BN WB Antibody Cocktail | Invitrogen   | Cat# 45-7999; RRID:AB_2533834                   |
| anti-COX I (1D6)            | Santa Cruz      | Cat# sc-58347; RRID:AB_2229888                  |
| anti-HSP60                  | Abcam           | Cat# ab46798; RRID:AB_881444                    |
| anti-mtHSP70 (JG1)          | Thermo Fisher Scientific | Cat# MA3-028; RRID:AB_325474        |
| anti-TID1 (EPR12414)        | Abcam           | Cat# ab181024                                  |
| anti-LONP1                  | Abcam           | Cat# ab103809; RRID:AB_10858161                 |
| anti-CLPP (EPR12414)        | Abcam           | Cat# ab124822; RRID:AB_10975619                 |
| anti-CHOP (L63F7)           | Cell Signaling  | Cat# 2895; RRID:AB_2089254                     |
| anti-GRP78 (C50B12)         | Cell Signaling  | Cat# 3177; RRID:AB_2119845                     |
| anti-XBP1                   | Santa Cruz      | Cat# sc-8015; RRID:AB_628449                   |
| anti-α-tubulin              | Sigma Aldrich   | Cat# T5168; RRID:AB_477579                     |
| anti-phospho-AKT-Ser473     | Cell Signaling  | Cat# 9271; RRID:AB_329825                      |
| anti-phospho-AKT-Thr308 (244F9) | Cell Signaling | Cat# 4056; RRID:AB_331163                      |
| anti-AKT                    | Cell Signaling  | Cat# 9272; RRID:AB_329827                      |
| anti-phospho-GSK3α/β-Ser21/9 | Cell Signaling | Cat# 9331; RRID:AB_329830                      |
| anti-GSK3β                  | Cell Signaling  | Cat #9315S; RRID:AB_490890                     |
| anti-Caspase3               | Cell Signaling  | Cat# 9662; RRID:AB_331439                     |
| anti-PARP1 (F-2)            | Santa Cruz      | Cat# sc-8007; RRID:AB_628105                   |
| anti-PGC1α                  | Abcam           | Cat# ab54481; RRID:AB_881987                   |
| anti-PGC1β                  | Abcam           | Cat# ab61249; RRID:AB_946298                   |
| Antibody Description                | Manufacturer   | Catalog Number | RRID          |
|-----------------------------------|----------------|----------------|---------------|
| anti-mtTFA (E-16)                 | Santa Cruz     | Cat# sc-30963; RRID:AB_2255881 |
| anti-NRF2                          | Cell Signaling | Cat# 4399; RRID:AB_1950359    |
| anti-UCP1                          | Abcam          | Cat# ab10983; RRID:AB_2241462 |
| anti-phospho-CREB-Ser133           | Cell Signaling | Cat# 9191; RRID:AB_331606     |
| anti-CREB (48H2)                   | Cell Signaling | Cat# 9197; RRID:AB_331277     |
| anti-phospho-PKA-Thr197            | Cell Signaling | Cat# 5661; RRID:AB_10707163   |
| anti-PKA                          | Cell Signaling | Cat# 4782; RRID:AB_2170170    |
| anti-ATGL                         | Cell Signaling | Cat# 2138s; RRID:AB_2167955   |
| anti-GAPDH (14C10)                | Cell Signaling | Cat# 2118; RRID:AB_561053     |
Reference

Caraux, G., and Pinloche, S. (2005). PermutMatrix: a graphical environment to arrange gene expression profiles in optimal linear order. Bioinformatics 21, 1280-1281.

Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols 4, 44-57.

Kang, S.G., Yi, H.S., Choi, M.J., Ryu, M.J., Jung, S., Chung, H.K., Chang, J.Y., Kim, Y.K., Lee, S.E., Kim, H.W., et al. (2017). ANGPTL6 expression is coupled with mitochondrial OXPHOS function to regulate adipose FGF21. The Journal of endocrinology 233, 105-118.

Kim, D., Langmead, B., and Salzberg, S.L. (2015). HISAT: a fast spliced aligner with low memory requirements. Nature methods 12, 357-360.

Kwon, M.C., Koo, B.K., Moon, J.S., Kim, Y.Y., Park, K.C., Kim, N.S., Kwon, M.Y., Kong, M.P., Yoon, K.J., Im, S.K., et al. (2008). Crif1 is a novel transcriptional coactivator of STAT3. The EMBO journal 27, 642-653.

Mi, H., Muraganujan, A., Casagrande, J.T., and Thomas, P.D. (2013). Large-scale gene function analysis with the PANTHER classification system. Nature protocols 8, 1551-1566.

Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E., et al. (2003). PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature genetics 34, 267-273.

Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 102, 15545-15550.

Tan, C.M., Chen, E.Y., Dannenfelser, R., Clark, N.R., and Ma'ayan, A. (2013). Network2Canvas: network visualization on a canvas with enrichment analysis. Bioinformatics 29, 1872-1878.

Yi, H.S., Lee, Y.S., Byun, J.S., Seo, W., Jeong, J.M., Park, O., Duester, G., Haseba, T., Kim, S.C., Park, K.G., et al. (2014). Alcohol dehydrogenase III exacerbates liver fibrosis by enhancing stellate cell activation and suppressing natural killer cells in mice. Hepatology 60, 1044-1053.